

US008628776B2

(12) **United States Patent**
Throsby et al.(10) **Patent No.:** **US 8,628,776 B2**
(45) **Date of Patent:** **Jan. 14, 2014**(54) **HUMAN BINDING MOLECULES AGAINST
ENTEROCOCCI AND STAPHYLOCOCCUS**2005/0180986 A1 8/2005 Rich et al.
2006/0002939 A1 1/2006 Fischer et al.
2009/0104204 A1 4/2009 Throsby et al.(75) Inventors: **Mark Throsby**, Utrecht (NL); **Robert Arjen Kramer**, Utrecht (NL); **Cornelis Adriaan De Kruif**, De Bilt (NL)

FOREIGN PATENT DOCUMENTS

(73) Assignee: **Crucell Holland B.V.**, Leiden (NL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/550,100**(22) Filed: **Jul. 16, 2012**(65) **Prior Publication Data**

US 2012/0315278 A1 Dec. 13, 2012

Related U.S. Application Data

(60) Continuation of application No. 13/068,784, filed on May 19, 2011, now Pat. No. 8,241,631, which is a division of application No. 12/227,116, filed as application No. PCT/EP2007/055535 on Jun. 5, 2007, now Pat. No. 7,960,518.

(60) Provisional application No. 60/811,542, filed on Jun. 6, 2006.

(30) **Foreign Application Priority Data**Jun. 6, 2006 (EP) 06115013
Jul. 6, 2006 (EP) 06116719
Sep. 26, 2006 (EP) 06121258
Mar. 6, 2007 (EP) 07103587(51) **Int. Cl.**
A61K 39/395 (2006.01)
C07K 16/00 (2006.01)(52) **U.S. Cl.**
USPC **424/142.1**; 424/150.1; 424/178.1;
530/388.15; 530/388.2(58) **Field of Classification Search**
None
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

4,901,307 A 2/1990 Gilhousen et al.
5,103,459 A 4/1992 Gilhousen et al.
5,696,108 A 12/1997 Heath, Jr. et al.
5,914,950 A 6/1999 Tiedemann et al.
6,094,428 A 7/2000 Bruckert et al.
6,122,291 A 9/2000 Robinson et al.
6,248,329 B1* 6/2001 Chandrashekar et al. . 424/191.1
6,265,150 B1 7/2001 Terstappen et al.
6,335,922 B1 1/2002 Tiedemann et al.
6,473,395 B1 10/2002 Lee
6,908,994 B1 6/2005 Rich et al.
7,244,430 B2 7/2007 Throsby et al.
7,537,764 B2 5/2009 Throsby et al.EP 1134994 9/2001
JP 09-018450 1/1997
JP 11-234204 8/1999
JP 00-078146 3/2000
JP 01-036463 2/2001
WO WO 84/03564 9/1984
WO WO 93/09872 5/1993
WO WO 97/33393 9/1997
WO WO 98/15833 4/1998
WO WO 98/30047 7/1998
WO WO 98/57994 12/1998
WO WO 99/18996 4/1999
WO WO 99/45660 9/1999
WO WO 00/25483 5/2000
WO WO 00/63403 10/2000
WO WO 01/54335 7/2001
WO WO 01/71926 9/2001
WO WO 02/103012 A1 12/2002
WO WO 03/059259 A2 7/2003
WO WO 03/059260 A 7/2003
WO WO 03/072607 9/2003
WO WO 2004/043405 5/2004
WO WO 2005/103084 A2 11/2005
WO WO 2005-118644 A2 12/2005
WO WO 2006/067122 A2 6/2006
WO WO 2007/141278 A2 12/2007

OTHER PUBLICATIONS

Chen et al, The EMBO Journal 14(12):2784-2794, 1995.*
Kussie et al, Journal of Immunology, 152:146-152, 1994.*
Feng et al (Infection and Immunity, 64(1):363-365, 1996).*
Bowie et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions; Science, 1990, pp. 1306-1310, vol. 247.
Brown et al., Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody Vh CDR2; J. Immunol., 1996, pp. 3285-3291, vol. 156.
Campbell, Ailsa M.; Monoclonal Antibody Technology; 1984, Elsevier Science Publishing Co. 1984, Chapter 1, pp. 1-32.
Chen, et al.; Enhancement and destruction of antibody function by comatic mutation: unequal occurrence is controlled by V gene combinatorial associations; The EMBO Journal vol. 14 No. 12 pp. 2784-2794, 1995.
Cruse et al., Illustrated Diet. of Immunology, 2nd ed., CRC Press, 2003, p. 46.
Dorland's Medical Dictionary for Healthcare Consumers; definition of infection one page (http://www.mercksource.com/pp.us/cns/cns_h1_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/four/000053439.htm) taken from website Oct. 13, 2010.

(Continued)

Primary Examiner — Patricia A Duffy
(74) *Attorney, Agent, or Firm* — TraskBritt(57) **ABSTRACT**Described are human binding molecules specifically binding to *enterococci* and having killing activity against *enterococci*, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from *Enterococcus*.**10 Claims, 1 Drawing Sheet**

(56)

References Cited

OTHER PUBLICATIONS

International Preliminary Examination Report—PCT/US02/033929; IPEA/US Jul. 26, 2004.

International Search Report—PCT/US02/033929, International Searching Authority—European Patent Office, Jan. 30, 2003.

Kussie et al., A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity, *J. Immunol.*, 1994, pp. 146-152, vol. 152.

Lu, et al.; Unified power control, error correction coding and scheduling for a CDMA downlink system; *Wireless Networks 2* (1997) pp. 83-90.

PCT International Search Report, PCT/EP2007/055527, dated Jan. 29, 2008.

PCT International Search Report, PCT/EP2007/055535, dated Jun. 5, 2007.


Steadman's Online Medical Dictionary, definition of infection one page; <http://www.pdrel.com/View/Commone/PrintReady.aspx?printAreas=DocumentRetriveDiv>; taken from website Oct. 13, 2010.

Van Der Woude, Phase and Antigenic Variation in Bacteria; *Clinical Microbiology Reviews*, Jul. 2004, p. 581-611.

Roitt et al., *Immunology*, CV Mosby Company, 1985, p. 1.2.

Thomas et al., Protection from Lethal Gram-positive Infection by Macrophage Scavenger Receptor-dependent Phagocytosis, *J. Exp. Med.*, Jan. 3, 2000, pp. 147-155, vol. 191, No. 1., The Rockefeller University Press.

* cited by examiner



anti-enterococcal mAb
15 mg/kg (*7.5 mg/kg)

* $P < 0.05$ vs IgG1 Ctrl

**HUMAN BINDING MOLECULES AGAINST
ENTEROCOCCI AND STAPHYLOCOCCUS**

CROSS-REFERENCE TO RELATED
APPLICATION

This application is a continuation of U.S. patent application Ser. No. 13/068,784, filed May 19, 2011, U.S. Pat. No. 8,241,631, which is a divisional of U.S. patent application Ser. No. 12/227,116, filed Nov. 7, 2008, now U.S. Pat. No. 7,960,518 which is a national phase entry of PCT International Patent Application No. PCT/EP2007/055535, filed on Jun. 5, 2007, designating the United States of America, and published, in English, as PCT International Publication No. WO 2007/141278 A2 on Dec. 13, 2007, which itself claims the benefit under Article 8 of the PCT of EP 06115013.2, filed Jun. 6, 2006, EP 06116719.2, filed Jul. 6, 2006, EP 06121258.5, filed on Sep. 26, 2006, and EP 07103587.7 filed on Mar. 6, 2007 and under Article 8 of the PCT and 35 U.S.C. §119 (e) of U.S. patent application Ser. No. 60/811,542, filed Jun. 6, 2006, the contents of the entirety of each of which are incorporated herein by this reference.

STATEMENT ACCORDING TO 37 C.F.R.
§1.52(e)(5)—SEQUENCE LISTING SUBMITTED
ON COMPACT DISC

Pursuant to 37 C.F.R. §1.821(c) or (e), a file containing an ASCII text version of the Sequence Listing has been submitted concomitant with this application, the contents of which are hereby incorporated by reference.

TECHNICAL FIELD

The disclosure relates generally to biotechnology and medicine. In particular, the disclosure relates to the diagnosis, prophylaxis and/or treatment of infection, such as by *Enterococci*.

BACKGROUND

Enterococci are gram-positive, facultatively anaerobic bacteria of the family Enterococcaceae. They were previously classified as Group D streptococci. *Enterococci* are found in the bowels of most humans and are commonly isolated from stool, urine and sites of intra-abdominal and lower extremity infection. Bacteria of the genus *Enterococcus* are often regarded as harmless commensals of the gastrointestinal tract, but within the last 10 years they have become an important cause of nosocomial (hospital-acquired) infections, not because of increased virulence but because of antibiotic resistance. It has been estimated in the United States of America, that 800,000 cases of enterococcal infection occur each year resulting in costs of around \$500 million. To infect hosts, *enterococci* primarily colonize mucosal surfaces. *Enterococci* are aetiological agents of bacteraemia, surgical wound infections, urinary tract infections, and endocarditis. They are also associated with obligate anaerobes in mixed infections that result in intra-abdominal abscesses. Overall, there are about seventeen species of *enterococci*, among which *Enterococcus faecalis* and *Enterococcus faecium* appear to be the most commonly detected in human feces. *E. faecalis* accounts for most of the enterococcal infections of humans, usually representing 80-90% of clinical isolates. *E. faecium* is detected much less frequently but is nevertheless of significance because of a high incidence of multiple resistances to antibacterial agents. Enterococcal infections are commonly

treated with antimicrobials and until recently they have been adequately controlled using these agents. However, drug-resistant enterococcal strains are emerging, and infection by strains resistant to all presently available antibiotics may become a serious problem in the near future. Some *enterococci* have already acquired intrinsic resistance to β -lactam-based antibiotics (penicillins) as well as many aminoglycosides. In the last two decades, particularly virulent strains of *Enterococcus* which are even resistant to the antibiotic vancomycin (Vancomycin-Resistant *Enterococcus*, or VRE) have emerged in nosocomial infections of hospitalized patients. Despite the urgent need for the development of new antibiotics, the major pharmaceutical companies appear to have lost interest in the antibiotic market. In 2002, only 5 out of the more than 500 drugs in phase II or phase III clinical development were new antibiotics. In the last 6 years only 10 antibiotics have been registered and only 2 of those did not exhibit cross-reactivity with existing drugs (and thus not subject to the same patterns of drug resistance). This trend has been attributed to several factors: the cost of new drug development and the relatively small return on investment that infectious disease treatments yield compared to drugs against hypertension, arthritis and lifestyle drugs e.g. for impotence. Another contributing factor is the increasing difficulty in finding new targets, further driving up development costs. Therefore, investigation into novel therapies or preventative measures for (multi-drug-resistant) bacterial infections is urgently needed to meet this impending healthcare crisis.

Active immunization with vaccines and passive immunization with immunoglobulins are promising alternatives to classical small molecule therapy. A few bacterial diseases that once caused widespread illness, disability, and death can now be prevented through the use of vaccines. The vaccines are based on weakened (attenuated) or dead bacteria, components of the bacterial surface or on inactivated toxins. The immune response raised by a vaccine is mainly directed to immunogenic structures, a limited number of proteins or sugar structures on the bacteria that are actively processed by the immune system. Since these immunogenic structures are very specific to the organism, the vaccine needs to comprise the immunogenic components of all variants of the bacteria against which the vaccine should be protective. As a consequence thereof, vaccines are very complex, take long and are expensive to develop. Further complicating the design of vaccines is the phenomenon of 'antigen replacement'. This occurs when new strains become prevalent that are serologically and thus antigenically distinct from those strains covered by the vaccines. The immune status of the populations at risk for nosocomial infections further complicates vaccine design. These patients are inherently unwell and may even be immunocompromised (due to the effect of immunosuppressive drugs) resulting in delayed or insufficient immunity against the infecting pathogens. Furthermore, except in the case of certain elective procedures, it may not be possible to identify and vaccinate the at risk patients in time to give them sufficient immune protection from infection.

Direct administration of therapeutic immunoglobulins, also referred to as passive immunization, does not require an immune response from the patient and therefore gives immediate protection. In addition, passive immunization can be directed to bacterial structures that are not immunogenic and that are less specific to the organism. Passive immunization against pathogenic organisms has been based on immunoglobulins derived from sera of human or non-human donors. However, blood-derived products have potential health risks inherently associated with these products. In addition, the immunoglobulins can display batch-to-batch variation and

may be of limited availability in case of sudden mass exposures. Recombinantly produced antibodies do not have these disadvantages and thus offer an opportunity to replace immunoglobulins derived from sera.

Murine monoclonal antibodies directed against enterococcal antigens are known in the art (see, WO 03/072607). However, murine antibodies are limited for their use in vivo due to problems associated with administration of murine antibodies to humans, such as short serum half life, an inability to trigger certain human effector functions and elicitation of an unwanted dramatic immune response against the murine antibody in a human (HAMA).

WO 99/18996 relates to *enterococcus* antigens and vaccines. WO 99/18996 further discloses rabbit antiserum against conjugated purified antigens from *enterococci*, and opsonic activity of such antiserum.

Although WO 99/18996 refers to human antibodies as desired molecules, the antibodies actually disclosed and used therein are of rabbit origin, and this document actually does not actually disclose any human antibodies, and does not disclose sequences thereof.

SUMMARY

Disclosed are human binding molecules capable of specifically binding to *enterococci* and exhibiting killing and/or growth inhibiting activity against *enterococci*. The disclosure also pertains to nucleic acid molecules encoding at least the binding region of the human binding molecules. Further provided for is for the use of the human binding molecules hereof in the prophylaxis and/or treatment of a subject having, or at risk of developing, an *Enterococcus* infection. Besides that, the disclosure pertains to the use of the human binding molecules in the diagnosis/detection of *Enterococcus*.

DESCRIPTION OF THE FIGURES

FIG. 1 shows data of an in vivo experiment. On the Y-axis CFU/ml in blood of mice is shown, while on the X-axis the respective antibodies are depicted. The antibodies were used in an amount of 15 mg/kg, with the exception of CR6016 and CR6241 which were used in an amount of 7.5 mg/kg. With the exception of CR6043 and CR6071 all of the antibodies had a median that differed significantly with that of the control IgG (P<0.05 vs. IgG1 Ctrl.).

DETAILED DESCRIPTION

The term "amino acid sequence" as used herein refers to naturally occurring or synthetic molecules and to a peptide, oligopeptide, polypeptide or protein sequence.

As used herein the term "binding molecule" refers to an intact immunoglobulin including monoclonal antibodies, such as chimeric, humanized or human monoclonal antibodies, or to an antigen-binding and/or variable domain comprising fragment of an immunoglobulin that competes with the intact immunoglobulin for specific binding to the binding partner of the immunoglobulin, e.g. *enterococci*. Regardless of structure, the antigen-binding fragment binds with the same antigen that is recognized by the intact immunoglobulin. An antigen-binding fragment can comprise a peptide or polypeptide comprising an amino acid sequence of at least 2 contiguous amino acid residues, at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 30 contiguous amino acid residues, at least

35 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino acid residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues, or at least 250 contiguous amino acid residues of the amino acid sequence of the binding molecule.

The term "binding molecule", as used herein includes all immunoglobulin classes and subclasses known in the art. Depending on the amino acid sequence of the constant domain of their heavy chains, binding molecules can be divided into the five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4.

Antigen-binding fragments include, inter alia, Fab, F(ab'), F(ab')₂, Fv, dAb, Fd, complementarity determining region (CDR) fragments, single-chain antibodies (scFv), bivalent single-chain antibodies, single-chain phage antibodies, diabodies, triabodies, tetrabodies, peptides or polypeptides that contain at least a fragment of an immunoglobulin that is sufficient to confer specific antigen binding to the (poly) peptide, etc. The above fragments may be produced synthetically or by enzymatic or chemical cleavage of intact immunoglobulins or they may be genetically engineered by recombinant DNA techniques. The methods of production are well-known in the art and are described, for example, in *Antibodies: A Laboratory Manual*, Edited by: E. Harlow and D. Lane (1988), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., which is incorporated herein by reference. A binding molecule or antigen-binding fragment thereof may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or they may be different.

The binding molecule can be a naked or unconjugated binding molecule but can also be part of an immunoconjugate. A naked or unconjugated binding molecule is intended to refer to a binding molecule that is not conjugated, operatively linked or otherwise physically or functionally associated with an effector moiety or tag, such as inter alia a toxic substance, a radioactive substance, a liposome, an enzyme. It will be understood that naked or unconjugated binding molecules do not exclude binding molecules that have been stabilized, multimerized, humanized or in any other way manipulated, other than by the attachment of an effector moiety or tag. Accordingly, all post-translationally modified naked and unconjugated binding molecules are included herewith, including where the modifications are made in the natural binding molecule-producing cell environment, by a recombinant binding molecule-producing cell, and are introduced by the hand of man after initial binding molecule preparation. Of course, the term naked or unconjugated binding molecule does not exclude the ability of the binding molecule to form functional associations with effector cells and/or molecules after administration to the body, as some of such interactions are necessary in order to exert a biological effect. The lack of associated effector group or tag is therefore applied in definition to the naked or unconjugated binding molecule in vitro, not in vivo.

As used herein, the term "biological sample" encompasses a variety of sample types, including blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures, or cells derived therefrom

and the progeny thereof. The term also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as proteins or polynucleotides. The term encompasses various kinds of clinical samples obtained from any species, and also includes cells in culture, cell supernatants and cell lysates.

The term “complementarity determining regions” (CDR) as used herein means sequences within the variable regions of binding molecules, such as immunoglobulins, that usually contribute to a large extent to the antigen binding site which is complementary in shape and charge distribution to the epitope recognized on the antigen. The CDR regions can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, e.g., by solubilization in SDS. Epitopes may also consist of posttranslational modifications of proteins.

The term “deletion”, as used herein, denotes a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent as compared to the parent, often the naturally occurring, molecule.

The term “expression-regulating nucleic acid sequence” as used herein refers to polynucleotide sequences necessary for and/or affecting the expression of an operably linked coding sequence in a particular host organism. The expression-regulating nucleic acid sequences, such as inter alia appropriate transcription initiation, termination, promoter, enhancer sequences; repressor or activator sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion, can be any nucleic acid sequence showing activity in the host organism of choice and can be derived from genes encoding proteins, which are either homologous or heterologous to the host organism. The identification and employment of expression-regulating sequences is routine to the person skilled in the art.

The term “functional variant”, as used herein, refers to a binding molecule that comprises a nucleotide and/or amino acid sequence that is altered by one or more nucleotides and/or amino acids compared to the nucleotide and/or amino acid sequences of the parental binding molecule and that is still capable of competing for binding to the binding partner, e.g. *enterococci*, with the parental binding molecule. In other words, the modifications in the amino acid and/or nucleotide sequence of the parental binding molecule do not significantly affect or alter the binding characteristics of the binding molecule encoded by the nucleotide sequence or containing the amino acid sequence, i.e. the binding molecule is still able to recognize and bind its target. The functional variant may have conservative sequence modifications including nucleotide and amino acid substitutions, additions and deletions. These modifications can be introduced by standard techniques known in the art, such as site-directed mutagenesis and random PCR-mediated mutagenesis, and may comprise natural as well as non-natural nucleotides and amino acids.

Conservative amino acid substitutions include the ones in which the amino acid residue is replaced with an amino acid residue having similar structural or chemical properties. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid),

uncharged polar side chains (e.g., asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan). Other classifications of amino acid residue families than the one used hereinbefore can also be employed. Furthermore, a variant may have non-conservative amino acid substitutions, e.g., replacement of an amino acid with an amino acid residue having different structural or chemical properties. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing immunological activity may be found using computer programs well-known in the art.

A mutation in a nucleotide sequence can be a single alteration made at a locus (a point mutation), such as transition or transversion mutations, or alternatively, multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleotide sequence. The mutations may be performed by any suitable method known in the art.

The term “host”, as used herein, is intended to refer to an organism or a cell into which a vector such as a cloning vector or an expression vector has been introduced. The organism or cell can be prokaryotic or eukaryotic. It should be understood that this term is intended to refer not only to the particular subject organism or cell, but to the progeny of such an organism or cell as well. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent organism or cell, but are still included within the scope of the term “host” as used herein.

The term “human”, when applied to binding molecules as defined herein, refers to molecules that are either directly derived from a human or based upon a human sequence. When a binding molecule is derived from or based on a human sequence and subsequently modified, it is still to be considered human as used throughout the specification. In other words, the term human, when applied to binding molecules is intended to include binding molecules having variable and constant regions derived from human germline immunoglobulin sequences or based on variable or constant regions occurring in a human or human lymphocyte and modified in some form. Thus, the human binding molecules may include amino acid residues not encoded by human germline immunoglobulin sequences; comprise substitutions and/or deletions (e.g., mutations introduced by for instance random or site-specific mutagenesis in vitro or by somatic mutation in vivo). “Based on” as used herein refers to the situation that a nucleic acid sequence may be exactly copied from a template, or with minor mutations, such as by error-prone PCR methods, or synthetically made matching the template exactly or with minor modifications. Semi-synthetic molecules based on human sequences are also considered to be human as used herein.

The term “insertion”, also known as the term “addition”, denotes a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the parent sequence.

The term “intrinsic activity”, when applied to binding molecules as defined herein, refers to binding molecules that are capable of binding to certain protein or carbohydrate antigens on the surface of pathogens such as bacteria and that can inhibit the ability of the pathogen to grow and divide nor-

mally. Such binding molecules can for example block the entry of specific nutrients required for growth or the transport of toxic waste elements from the bacteria. Through the latter action they may also increase the sensitivity of bacteria to the action of antibiotic drugs.

The term "isolated", when applied to binding molecules as defined herein, refers to binding molecules that are substantially free of other proteins or polypeptides, particularly free of other binding molecules having different antigenic specificities, and are also substantially free of other cellular material and/or chemicals. For example, when the binding molecules are recombinantly produced, they are preferably substantially free of culture medium, and when the binding molecules are produced by chemical synthesis, they are preferably substantially free of chemical precursors or other chemicals, i.e., they are separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. The term "isolated" when applied to nucleic acid molecules encoding binding molecules as defined herein, is intended to refer to nucleic acid molecules in which the nucleotide sequences encoding the binding molecules are free of other nucleotide sequences, particularly nucleotide sequences encoding binding molecules that bind binding partners other than *enterococci*. Furthermore, the term "isolated" refers to nucleic acid molecules that are substantially separated from other cellular components that naturally accompany the native nucleic acid molecule in its natural host, e.g., ribosomes, polymerases, or genomic sequences with which it is naturally associated. Moreover, "isolated" nucleic acid molecules, such as cDNA molecules, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope. Accordingly, the term "human monoclonal antibody" refers to an antibody displaying a single binding specificity which has variable and constant regions derived from or based on human germline immunoglobulin sequences or derived from completely synthetic sequences. The method of preparing the monoclonal antibody is not relevant.

The term "naturally occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally occurring.

The term "nucleic acid molecule" as used herein refers to a polymeric form of nucleotides and includes both sense and anti-sense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. The term also includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages. The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phospho-

nates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids, etc.). The above term is also intended to include any topological conformation, including single-stranded, double-stranded, partially duplexed, triplex, hairpinned, circular and pad-locked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule. A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, e.g., for anti-sense therapy, hybridization probes and PCR primers.

The term "operably linked" refers to two or more nucleic acid sequence elements that are usually physically linked and are in a functional relationship with each other. For instance, a promoter is operably linked to a coding sequence, if the promoter is able to initiate or regulate the transcription or expression of a coding sequence, in which case the coding sequence should be understood as being "under the control of" the promoter.

"Opsonic activity" refers to the ability of an opsonin (generally either a binding molecule, e.g. an antibody, or serum complement factors) to bind to the surface of a pathogen either by specific antigenic recognition (in the case of antibodies) or through the catalytic effect of surface bound molecules (e.g. the increased deposition of C3b as a result of surface bound antibodies). Phagocytosis of opsonized pathogens is enhanced due to the specific recognition of receptors on the phagocyte for the opsonin (the Fc receptor in case the antibodies themselves are the opsonins and the complement receptor in case complement is the opsonin). Certain bacteria, especially encapsulated bacteria that resist phagocytosis due to the presence of the capsule, become extremely attractive to phagocytes such as neutrophils and macrophages when coated with an opsonic antibody and their rate of clearance from the bloodstream and infected organs is strikingly enhanced. Opsonic activity may be measured in any conventional manner (e.g. the opsonic phagocytic killing assay).

By "pharmaceutically acceptable excipient" is meant any inert substance that is combined with an active molecule such as a drug, agent, or binding molecule for preparing an agreeable or convenient dosage form. The "pharmaceutically acceptable excipient" is an excipient that is non-toxic to recipients at the dosages and a concentration employed, and is compatible with other ingredients of the formulation comprising the drug, agent or binding molecule.

The term "specifically binding", as used herein, in reference to the interaction of a binding molecule, e.g. an antibody, and its binding partner, e.g. an antigen, means that the interaction is dependent upon the presence of a particular structure, e.g. an antigenic determinant or epitope, on the binding partner. In other words, the antibody preferentially binds or recognizes the binding partner even when the binding partner is present in a mixture of other molecules or organisms. The binding may be mediated by covalent or non-covalent interactions or a combination of both. In yet other words, the term "specifically binding" means immunospecifically binding to an antigen or a fragment thereof and not immunospecifically

binding to other antigens. A binding molecule that immunospecifically binds to an antigen may bind to other peptides or polypeptides with lower affinity as determined by, e.g., radioimmunoassays (RIA), enzyme-linked immunosorbent assays (ELISA), BIACORE, or other assays known in the art. Binding molecules or fragments thereof that immunospecifically bind to an antigen may be cross-reactive with related antigens. Preferably, binding molecules or fragments thereof that immunospecifically bind to an antigen do not cross-react with other antigens.

A "substitution", as used herein, denotes the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

The term "therapeutically effective amount" refers to an amount of the binding molecule as defined herein that is effective for preventing, ameliorating and/or treating a condition resulting from infection with *Enterococcus*.

The term "treatment" refers to therapeutic treatment as well as prophylactic or preventative measures to cure or halt or at least retard disease progress. Those in need of treatment include those already inflicted with a condition resulting from infection with *Enterococcus* as well as those in which infection with *Enterococcus* is to be prevented. Subjects partially or totally recovered from infection with *Enterococcus* might also be in need of treatment. Prevention encompasses inhibiting or reducing the spread of *Enterococcus* or inhibiting or reducing the onset, development or progression of one or more of the symptoms associated with infection with *Enterococcus*.

The term "vector" denotes a nucleic acid molecule into which a second nucleic acid molecule can be inserted for introduction into a host where it will be replicated, and in some cases expressed. In other words, a vector is capable of transporting a nucleic acid molecule to which it has been linked. Cloning as well as expression vectors are contemplated by the term "vector", as used herein. Vectors include, but are not limited to, plasmids, cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC) and vectors derived from bacteriophages or plant or animal (including human) viruses. Vectors comprise an origin of replication recognized by the proposed host and in case of expression vectors, promoter and other regulatory regions recognized by the host. A vector containing a second nucleic acid molecule is introduced into a cell by transformation, transfection, or by making use of viral entry mechanisms. Certain vectors are capable of autonomous replication in a host into which they are introduced (e.g., vectors having a bacterial origin of replication can replicate in bacteria). Other vectors can be integrated into the genome of a host upon introduction into the host, and thereby are replicated along with the host genome.

In a first aspect, disclosed are binding molecules capable of specifically binding to an *Enterococcus* species. The binding molecules may be human binding molecules. The binding molecules may exhibit killing activity against an *Enterococcus* species. In a further aspect, the binding molecules hereof are capable of specifically binding to and/or have killing activity against at least two different *Enterococcus* species. Preferably, the binding molecules hereof are capable of specifically binding to and/or have killing activity against at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen different *Enterococcus* species. *Enterococcus* species that the binding molecules hereof are capable of specifically binding to and/or have killing activity against are selected from the group consisting of *E.*

asini, *E. avium*, *E. casseliflavus*, *E. cecorum*, *E. columbae*, *E. dispar*, *E. durans*, *E. faecalis*, *E. faecium*, *E. flavescens*, *E. gallinarum*, *E. gilvus*, *E. haemoperxidus*, *E. hirae*, *E. malodoratus*, *E. moraviensis*, *E. mundtii*, *E. pallens*, *E. porcinus*, *E. pseudoavium*, *E. raffinosus*, *E. ratti*, *E. saccharolyticus*, *E. seriolicida*, *E. solitarius*, *E. sulfureus*, *E. villorum*, with *E. faecalis* and *E. faecium* being preferred species. In an embodiment the binding molecules hereof are capable of specifically binding to and have killing activity against different strains within one *Enterococcus* species. In another embodiment, the binding molecules hereof may even be capable of specifically binding to and/or have killing activity against at least one other Gram-positive bacterium and/or Gram-negative bacterium including, but not limited to, Group A streptococci; *Streptococcus pyrogenes*, Group B streptococci; *Streptococcus agalactiae*, *Streptococcus milleri*, *Streptococcus pneumoniae*, Viridans streptococci; *Streptococcus mutans*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Corynebacterium diphtheriae*, *Corynebacterium ulcerans*, *Corynebacterium pseudotuberculosis*, *Corynebacterium jeikeium*, *Corynebacterium xerosis*, *Corynebacterium pseudodiphtheriticum*, *Bacillus anthracis*, *Bacillus cereus*, *Listeria monocytogenes*, *Clostridium perfringens*, *Clostridium tetani*, *Clostridium botulinum*, *Clostridium difficile*, *Mycobacterium tuberculosis*, *Mycobacterium leprae*, *Actinomyces israelii*, *Nocardia asteroides*, *Nocardia brasiliensis*, *Escherichia coli*, *Proteus mirabilis*, *Proteus vulgaris*, *Klebsiella pneumoniae*, *Salmonella typhi*, *Salmonella paratyphi A, B & C*, *Salmonella enteritidis*, *Salmonella cholerae-suis*, *Salmonella virchow*, *Salmonella typhimurium*, *Shigella dysenteriae*, *Shigella boydii*, *Shigella flexneri*, *Shigella sonnei*, *Pseudomonas aeruginosa*, *Pseudomonas mallei*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificus*, *Vibrio alginolyticus*, *Campylobacter pylori*, *Helicobacter pylori*, *Campylobacter jejuni*, *Bacteroides fragilis*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Branhamella catarrhalis*, *Haemophilus influenzae*, *Haemophilus ducreyi*, *Bordetella pertussis*, *Brucella abortus*, *Brucella abortus*, *Brucella melitensis*, *Legionella pneumophila*, *Treponema pallidum*, *Treponema carateum*, *Leptospira interrogans*, *Leptospira biflexa*, *Borrelia recurrentis*, *Borrelia burgdorferi*, *Mycoplasma pneumoniae*, *Coxiella burnetii*, *Chlamydia trachomatis*, *Chlamydia psittaci*, *Chlamydia pneumoniae*. The binding molecules hereof may be capable of specifically binding to *enterococci* and optionally other Gram-positive and/or Gram-negative bacteria that are viable, living and/or infective or that are in inactivated/attenuated form. Methods for inactivating/attenuating bacteria are well-known in the art and include, but are not limited to, antibiotic treatment, UV treatment, formaldehyde treatment, etc.

The binding molecules may also specifically bind to one or more fragments of *enterococci* (and other Gram-positive and/or Gram-negative bacteria) such as inter alia a preparation of one or more proteins and/or peptides or polypeptides derived from *enterococci* or one or more recombinantly produced enterococcal proteins and/or polypeptides. For methods of treatment and/or prevention of enterococcal infections the binding molecules may be capable of specifically binding to surface accessible proteins of *enterococci*. For diagnostic purposes, the binding molecules may also be capable of specifically binding to proteins not present on the surface of *enterococci*. The nucleotide and/or amino acid sequence of proteins of various *Enterococcus* species and strains can be found in the GenBank-database, EMBL-database and/or other databases.

Alternatively, binding molecules hereof may also be capable of specifically binding to other enterococcal mol-

ecules including, but not limited to, surface factors that inhibit phagocytic engulfment; factors that enhance their survival in phagocytes; invasions that lyse eukaryotic cell membranes; exotoxins that damage host tissues or otherwise provoke symptoms of disease; polysaccharides; other cell wall components such as teichoic acid, lipoteichoic acid, ribitol, peptidoglycan, pentaglycine oligopeptide, N-acetylglucosamine, N-acetylmuramic acid, N-acetylgalactosaminuronic acid, N-acetylfucosamine, N-acetylglucosaminuronic acid, N-acetylmannosaminuronic acid, O-acetyl, glucosamine, muramic acid, galactosaminuronic acid, fucosamine, glucosaminuronic acid, mannosaminuronic acid rhamnose, hexosamine, hexose, kojibiose, glycerol phosphate, ribitol phosphate and linkage units between any of these components.

In another embodiment, the binding molecules are able to specifically bind to a fragment of the above-mentioned proteins and/or other molecules, wherein the fragment at least comprises an antigenic determinant recognized by the binding molecules hereof. An "antigenic determinant" as used herein is a moiety that is capable of binding to a binding molecule hereof with sufficiently high affinity to form a detectable antigen-binding molecule complex.

The binding molecules can be intact immunoglobulin molecules such as polyclonal or monoclonal antibodies or the binding molecules can be antigen-binding fragments including, but not limited to, Fab, F(ab'), F(ab')₂, Fv, dAb, Fd, complementarity determining region (CDR) fragments, single-chain antibodies (scFv), bivalent single-chain antibodies, single-chain phage antibodies, diabodies, triabodies, tetrabodies, and peptides or polypeptides that contain at least a fragment of an immunoglobulin that is sufficient to confer specific antigen binding to *enterococci* or a fragment thereof. In a preferred embodiment the binding molecules hereof are human monoclonal antibodies.

The binding molecules can be used in non-isolated or isolated form. Furthermore, the binding molecules hereof can be used alone or in a mixture comprising at least one binding molecule (or variant or fragment thereof) hereof. In other words, the binding molecules can be used in combination, e.g., as a pharmaceutical composition comprising two or more binding molecules hereof, variants or fragments thereof. For example, binding molecules having different, but complementary activities can be combined in a single therapy to achieve a desired prophylactic, therapeutic or diagnostic effect, but alternatively, binding molecules having identical activities can also be combined in a single therapy to achieve a desired prophylactic, therapeutic or diagnostic effect. Optionally, the mixture further comprises at least one other therapeutic agent. Preferably, the therapeutic agent such as e.g. an antibiotic is useful in the prophylaxis and/or treatment of an enterococcal infection.

Typically, the binding molecules hereof can bind to their binding partners, i.e. *enterococci* or fragments thereof, with an affinity constant (K_d -value) that is lower than $0.2 \cdot 10^{-4}$ M, $1.0 \cdot 10^{-5}$ M, $1.0 \cdot 10^{-6}$ M, $1.0 \cdot 10^{-7}$ M, preferably lower than $1.0 \cdot 10^{-8}$ M, more preferably lower than $1.0 \cdot 10^{-9}$ M, more preferably lower than $1.0 \cdot 10^{-10}$ M, even more preferably lower than $1.0 \cdot 10^{-11}$ M, and in particular lower than $1.0 \cdot 10^{-12}$ M. The affinity constants can vary for antibody isotypes. For example, affinity binding for an IgM isotype refers to a binding affinity of at least about $1.0 \cdot 10^{-7}$ M. Affinity constants can for instance be measured using surface plasmon resonance, for example using the BIACORE system (Pharmacia Biosensor AB, Uppsala, Sweden).

The binding molecules may bind to *enterococci* or a fragment thereof in soluble form such as for instance in a sample

or in suspension or may bind to *enterococci* or a fragment thereof bound or attached to a carrier or substrate, e.g., microtiter plates, membranes and beads, etc. Carriers or substrates may be made of glass, plastic (e.g., polystyrene), polysaccharides, nylon, nitrocellulose, or Teflon, etc. The surface of such supports may be solid or porous and of any convenient shape. Furthermore, the binding molecules may bind to *enterococci* in purified/isolated or non-purified/non-isolated form.

Binding molecules exhibit killing activity. Killing activity as meant herein includes, but is not limited to, opsonic activity or any other activity increasing/augmenting/enhancing phagocytosis and/or phagocytic killing of bacteria, e.g. *enterococci*; intrinsic (killing) activity, e.g. reduce or inhibit bacterial growth or directly kill bacteria; increase the sensitivity of bacteria to antibiotic treatment; or any combination thereof. Opsonic activity can for instance be measured as described herein. Alternative assays measuring opsonic activity are described in for instance Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. Assays to measure the other mentioned activities are also known.

In a preferred embodiment, the binding molecules comprise at least a CDR3 region, preferably a heavy chain CDR3 region, comprising the amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:196, SEQ ID NO:202, SEQ ID NO:220, SEQ ID NO:226, SEQ ID NO:232, SEQ ID NO:238, SEQ ID NO:244, SEQ ID NO:250, SEQ ID NO:256, SEQ ID NO:262, SEQ ID NO:268, SEQ ID NO:274, SEQ ID NO:280, SEQ ID NO:286, SEQ ID NO:292, SEQ ID NO:298, SEQ ID NO:304, SEQ ID NO:310, SEQ ID NO:316, SEQ ID NO:322, SEQ ID NO:328, SEQ ID NO:334, SEQ ID NO:340, and SEQ ID NO:346. The CDR regions of the binding molecules hereof are shown in Table 11. CDR regions are according to Kabat et al. (1991) as described in Sequences of Proteins of Immunological Interest. In an embodiment binding molecules may comprise two, three, four, five or even all six CDR regions of the binding molecules.

In yet another embodiment, the binding molecules comprise a heavy chain comprising the variable heavy chain of the amino acid sequence selected from the group consisting of SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:211, SEQ ID NO:213, SEQ ID NO:395, SEQ ID NO:397, SEQ ID NO:399, SEQ ID NO:401, SEQ ID NO:403, SEQ ID NO:405, SEQ ID NO:407, SEQ ID NO:409, SEQ ID NO:411, SEQ ID NO:413, SEQ ID NO:415, SEQ ID NO:417, SEQ ID NO:419, SEQ ID NO:421, SEQ ID NO:423, SEQ ID NO:425, SEQ ID NO:427, SEQ ID NO:429, SEQ ID NO:431, SEQ ID NO:433, SEQ ID NO:435, and SEQ ID NO:437. In a further embodiment, the binding molecules comprise a light chain comprising the variable light chain of the amino acid sequence selected from the group consisting of SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:439, SEQ ID NO:441, SEQ ID NO:443, SEQ ID NO:445, SEQ ID NO:447, SEQ ID NO:449, SEQ ID NO:451, SEQ ID NO:453, SEQ ID NO:455, SEQ ID NO:457, SEQ ID NO:459, SEQ ID NO:461, SEQ ID NO:463, SEQ ID NO:465, SEQ ID NO:467, SEQ ID NO:469, SEQ ID NO:471, SEQ ID NO:473, SEQ ID

NO:475, SEQ ID NO:477, SEQ ID NO:479, and SEQ ID NO:481. Table 12 specifies the heavy and light chain variable regions of the binding molecule.

Another aspect hereof includes functional variants of the binding molecules as defined herein. Such molecules are considered to be functional variants of a binding molecule hereof, if the variants are capable of competing for specifically binding to *enterococci* (or other Gram-positive and/or Gram-negative bacteria) or a fragment thereof with the parental human binding molecules. In other words, the functional variants are still capable of binding to *enterococci* or a fragment thereof. Preferably, the functional variants are capable of competing for specifically binding to at least two (or more) different *Enterococcus* species or fragments thereof that are specifically bound by the parental human binding molecules. Furthermore, molecules are considered to be functional variants of a binding molecule hereof, if they have killing activity against *enterococci*, preferably against the at least two (or more) *Enterococcus* species against which the parental binding molecule exhibits killing activity.

In another embodiment, the functional variants of a binding molecule also have killing activity against other Gram-positive and/or Gram-negative bacteria. Functional variants include, but are not limited to, derivatives that are substantially similar in primary structural sequence, but which contain e.g. in vitro or in vivo modifications, chemical and/or biochemical, that are not found in the parental binding molecule. Such modifications include inter alia acetylation, acylation, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, cross-linking, disulfide bond formation, glycosylation, hydroxylation, methylation, oxidation, pegylation, proteolytic processing, phosphorylation, and the like.

Alternatively, functional variants can be binding molecules as defined herein comprising an amino acid sequence containing substitutions, insertions, deletions or combinations thereof of one or more amino acids compared to the amino acid sequences of the parental binding molecules. Furthermore, functional variants can comprise truncations of the amino acid sequence at either or both the amino or carboxyl termini. Functional variants according to the invention may have the same or different, either higher or lower, binding affinities compared to the parental binding molecule but are still capable of binding to *enterococci* or a fragment thereof. For instance, functional variants according to the invention may have increased or decreased binding affinities for *enterococci* or a fragment thereof compared to the parental binding molecules. Preferably, the amino acid sequences of the variable regions, including, but not limited to, framework regions, hypervariable regions, in particular the CDR3 regions, are modified. Generally, the light chain and the heavy chain variable regions comprise three hypervariable regions, comprising three CDRs, and more conserved regions, the so-called framework regions (FRs). The hypervariable regions comprise amino acid residues from CDRs and amino acid residues from hypervariable loops. Functional variants intended to fall within the scope hereof have at least about 50% to about 99%, preferably at least about 60% to about 99%, more preferably at least about 70% to about 99%, even more preferably at least about 80% to about 99%, most preferably at least about 90% to about 99%, in particular at least about 95% to about 99%, and in particular at least about 97% to about 99% amino acid sequence homology with the parental human binding molecules as defined herein. Computer algorithms such as inter alia Gap or Bestfit known to a person skilled in the art can be used to optimally align amino acid sequences to be compared and to define similar or identical amino acid

residues. Functional variants can be obtained by altering the parental binding molecules or parts thereof by general molecular biology methods known in the art including, but not limited to, error-prone PCR, oligonucleotide-directed mutagenesis, site-directed mutagenesis and heavy and/or light chain shuffling. In an embodiment the functional variants hereof have killing activity against *enterococci*. The killing activity may either be identical, or be higher or lower compared to the parental binding molecules. Furthermore, the functional variants having killing activity may have a further activity suitable in enterococcal control. Other activities are mentioned above. Henceforth, when the term (human) binding molecule is used, this also encompasses functional variants of the (human) binding molecule.

Provided is a panel of useful human monoclonal antibodies that have opsonic phagocytic killing activity against at least one strain of each of at least two different *Enterococcus* species and against at least one strain of *Staphylococcus aureus*. The antibodies hereof comprise variable regions of any one of antibodies CR5140 (SEQ ID NO's 395+439), CR5157 (SEQ ID NO's 397+441), CR6016 (SEQ ID NO's 88+108), CR6043 (SEQ ID NO's 90+110), CR6050 (SEQ ID NO's 401+445), CR6078 (SEQ ID NO's 96+116), CR6087 (SEQ ID NO's 211+215), CR6089 (SEQ ID NO's 213+217), CR6241 (SEQ ID NO's 98+118), CR6252 (SEQ ID NO's 100+120), CR6388 (SEQ ID NO's 421+465), CR6389 (SEQ ID NO's 423+467), CR6396 (SEQ ID NO's 425+469), CR6402 (SEQ ID NO's 427+471), CR6409 (SEQ ID NO's 429+473), CR6415 (SEQ ID NO's 431+475), CR6421 (SEQ ID NO's 433+477) or CR6429 (SEQ ID NO's 435+479) as disclosed herein, and antibodies comprising variable regions with sequences that are at least 80%, preferably at least 90%, more preferably at least 95%, identical thereto. Preferably the sequences of the complete antibodies are at least 80%, more preferably at least 90%, still more preferably at least 95% identical to the sequences of these antibodies as disclosed herein. These antibodies were all shown have opsonic phagocytic killing activity against at least two different *Enterococcus* species (comprising *E. faecalis* and *E. faecium*). Surprisingly, these antibodies were also reactive against *S. aureus* (strain 502, and for some antibodies (CR6252, CR6415, CR6421) it was further shown that they were also reactive against strain Numan of *S. aureus*, as well as against *S. epidermidis* strain RP62A), and thus have a broad specificity and broad potential for therapeutic use. These antibodies did not bind to LTA of *S. aureus*, which is one of the main constituents of the cell wall of *S. aureus*. In certain embodiments, the antibodies hereof therefore do not specifically bind to LTA of *S. aureus*. Also provided are compositions comprising at least 2, 3, 4, 5, or more, of the human monoclonal antibodies hereof. Of course, higher affinity mutants or mutants with other advantageous properties can be prepared according to routine methods, based on the sequences of the antibodies as disclosed herein. Such improved antibodies are included within the scope hereof, when the variable regions of heavy and light chain are at least 80%, preferably at least 90%, still more preferably at least 95% identical to the sequences of the variable regions of the antibodies disclosed herein.

Also provided are immunoconjugates, i.e. molecules comprising at least one binding molecule as defined herein and further comprising at least one tag, such as inter alia a detectable moiety/agent. Also contemplated herein are mixtures of immunoconjugates or mixtures of at least one immunoconjugate hereof and another molecule, such as a therapeutic agent or another binding molecule or immunoconjugate. In a further embodiment, the immunoconjugates may comprise more than one tag. These tags can be the same or distinct from

each other and can be joined/conjugated non-covalently to the binding molecules. The tag(s) can also be joined/conjugated directly to the human binding molecules through covalent bonding. Alternatively, the tag(s) can be joined/conjugated to the binding molecules by means of one or more linking compounds. Techniques for conjugating tags to binding molecules are well-known to the skilled artisan.

The tags of the immunoconjugates hereof may be therapeutic agents, but they can also be detectable moieties/agents. Tags suitable in therapy and/or prevention may be toxins or functional parts thereof, antibiotics, enzymes, other binding molecules that enhance phagocytosis or immune stimulation. Immunoconjugates comprising a detectable agent can be used diagnostically to, for example, assess if a subject has been infected with an *Enterococcus* species or monitor the development or progression of an enterococcal infection as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. However, they may also be used for other detection and/or analytical and/or diagnostic purposes. Detectable moieties/agents include, but are not limited to, enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and non-radioactive paramagnetic metal ions. The tags used to label the binding molecules for detection and/or analytical and/or diagnostic purposes depend on the specific detection/analysis/diagnosis techniques and/or methods used such as inter alia immunohistochemical staining of (tissue) samples, flow cytometric detection, scanning laser cytometric detection, fluorescent immunoassays, enzyme-linked immunosorbent assays (ELISA's), radioimmunoassays (RIA's), bioassays (e.g., phagocytosis assays), Western blotting applications, etc. Suitable labels for the detection/analysis/diagnosis techniques and/or methods known in the art are well within the reach of the skilled artisan.

Furthermore, the human binding molecules or immunoconjugates hereof can also be attached to solid supports, which are particularly useful for in vitro immunoassays or purification of *enterococci* or a fragment thereof. Such solid supports might be porous or nonporous, planar or non-planar. The binding molecules hereof can be fused to marker sequences, such as a peptide to facilitate purification. Examples include, but are not limited to, the hexa-histidine tag, the hemagglutinin (HA) tag, the myc tag or the flag tag. Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate. In another aspect, the binding molecules hereof may be conjugated/attached to one or more antigens. Preferably, these antigens are antigens which are recognized by the immune system of a subject to which the binding molecule-antigen conjugate is administered. The antigens may be identical, but may also differ from each other. Conjugation methods for attaching the antigens and binding molecules are well-known in the art and include, but are not limited to, the use of cross-linking agents. The binding molecules hereof will bind to *enterococci* and the antigens attached to the binding molecules will initiate a powerful T-cell attack on the conjugate, which will eventually lead to the destruction of the *enterococci*.

Next to producing immunoconjugates chemically by conjugating, directly or indirectly, via for instance a linker, the immunoconjugates can be produced as fusion proteins comprising the binding molecules hereof and a suitable tag. Fusion proteins can be produced by methods known in the art such as, e.g., recombinantly by constructing nucleic acid molecules comprising nucleotide sequences encoding the

binding molecules in frame with nucleotide sequences encoding the suitable tag(s) and then expressing the nucleic acid molecules.

Also provided is a nucleic acid molecule encoding at least a binding molecule, functional variant or immunoconjugate according to the invention. Such nucleic acid molecules can be used as intermediates for cloning purposes, e.g. in the process of affinity maturation as described herein. In a preferred embodiment, the nucleic acid molecules are isolated or purified.

The skilled person will appreciate that functional variants of these nucleic acid molecules are also intended to be a part hereof. Functional variants are nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the parental nucleic acid molecules.

Preferably, the nucleic acid molecules encode binding molecules comprising a CDR3 region, preferably a heavy chain CDR3 region, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:196, SEQ ID NO:202, SEQ ID NO:220, SEQ ID NO:226, SEQ ID NO:232, SEQ ID NO:238, SEQ ID NO:244, SEQ ID NO:250, SEQ ID NO:256, SEQ ID NO:262, SEQ ID NO:268, SEQ ID NO:274, SEQ ID NO:280, SEQ ID NO:286, SEQ ID NO:292, SEQ ID NO:298, SEQ ID NO:304, SEQ ID NO:310, SEQ ID NO:316, SEQ ID NO:322, SEQ ID NO:328, SEQ ID NO:334, SEQ ID NO:340, and SEQ ID NO:346. In a further embodiment the nucleic acid molecules encode binding molecules comprising two, three, four, five or even all six CDR regions of the binding molecules hereof.

In another embodiment, the nucleic acid molecules encode binding molecules comprising a heavy chain comprising the variable heavy chain of the amino acid sequence selected from the group consisting of SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:211, SEQ ID NO:213, SEQ ID NO:395, SEQ ID NO:397, SEQ ID NO:399, SEQ ID NO:401, SEQ ID NO:403, SEQ ID NO:405, SEQ ID NO:407, SEQ ID NO:409, SEQ ID NO:411, SEQ ID NO:413, SEQ ID NO:415, SEQ ID NO:417, SEQ ID NO:419, SEQ ID NO:421, SEQ ID NO:423, SEQ ID NO:425, SEQ ID NO:427, SEQ ID NO:429, SEQ ID NO:431, SEQ ID NO:433, SEQ ID NO:435, and SEQ ID NO:437. In another embodiment the nucleic acid molecules encode binding molecules comprising a light chain comprising the variable light chain of the amino acid sequence selected from the group consisting of SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:120, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:439, SEQ ID NO:441, SEQ ID NO:443, SEQ ID NO:445, SEQ ID NO:447, SEQ ID NO:449, SEQ ID NO:451, SEQ ID NO:453, SEQ ID NO:455, SEQ ID NO:457, SEQ ID NO:459, SEQ ID NO:461, SEQ ID NO:463, SEQ ID NO:465, SEQ ID NO:467, SEQ ID NO:469, SEQ ID NO:471, SEQ ID NO:473, SEQ ID NO:475, SEQ ID NO:477, SEQ ID NO:479, and SEQ ID NO:481.

Also provided are vectors, i.e. nucleic acid constructs, comprising one or more nucleic acid molecules according to the invention. Vectors can be derived from plasmids such as inter alia F, R1, RP1, Col, pBR322, TOL, Ti, etc; cosmids; phages such as lambda, lambdoid, M13, Mu, P1, P22, Q β ,

T-even, T-odd, T2, T4, T7, etc; plant viruses. Vectors can be used for cloning and/or for expression of the binding molecules hereof and might even be used for gene therapy purposes. Vectors comprising one or more nucleic acid molecules hereof operably linked to one or more expression-regulating nucleic acid molecules are also covered by the invention. The choice of the vector is dependent on the recombinant procedures followed and the host used. Introduction of vectors in host cells can be effected by inter alia calcium phosphate transfection, virus infection, DEAE-dextran mediated transfection, lipofectamin transfection or electroporation. Vectors may be autonomously replicating or may replicate together with the chromosome into which they have been integrated. Preferably, the vectors contain one or more selection markers. The choice of the markers may depend on the host cells of choice, although this is not critical to the invention as is well-known to persons skilled in the art. They include, but are not limited to, kanamycin, neomycin, puromycin, hygromycin, ZEOCIN®, thymidine kinase gene from Herpes simplex virus (HSV-TK), dihydrofolate reductase gene from mouse (dhfr). Vectors comprising one or more nucleic acid molecules encoding the human binding molecules as described above operably linked to one or more nucleic acid molecules encoding proteins or peptides that can be used to isolate the human binding molecules are also covered by the invention. These proteins or peptides include, but are not limited to, glutathione-S-transferase, maltose binding protein, metal-binding polyhistidine, green fluorescent protein, luciferase and beta-galactosidase.

Hosts containing one or more copies of the vectors mentioned above are an additional subject hereof. In certain embodiments, the hosts are host cells. Host cells include, but are not limited to, cells of mammalian, plant, insect, fungal or bacterial origin. Bacterial cells include, but are not limited to, cells from Gram-positive bacteria or Gram-negative bacteria such as several species of the genera *Escherichia*, such as *E. coli*, and *Pseudomonas*. In the group of fungal cells preferably yeast cells are used. Expression in yeast can be achieved by using yeast strains such as inter alia *Pichia pastoris*, *Saccharomyces cerevisiae* and *Hansenula polymorpha*. Furthermore, insect cells such as cells from *Drosophila* and Sf9 can be used as host cells. Besides that, the host cells can be plant cells such as inter alia cells from crop plants such as forestry plants, or cells from plants providing food and raw materials such as cereal plants, or medicinal plants, or cells from ornamentals, or cells from flower bulb crops. Transformed (transgenic) plants or plant cells are produced by known methods, for example, *Agrobacterium*-mediated gene transfer, transformation of leaf discs, protoplast transformation by polyethylene glycol-induced DNA transfer, electroporation, sonication, microinjection or bolistic gene transfer. Additionally, a suitable expression system can be a baculovirus system. Expression systems using mammalian cells such as Chinese Hamster Ovary (CHO) cells, COS cells, BHK cells or Bowes melanoma cells are preferred herein. Mammalian cells provide expressed proteins with posttranslational modifications that are most similar to natural molecules of mammalian origin. Since the invention deals with molecules that may have to be administered to humans, a completely human expression system would be particularly preferred. Therefore, even more preferably, the host cells are human cells. Examples of human cells are inter alia HeLa, 911, AT1080, A549, 293 and HEK293T cells. In preferred embodiments, the human producer cells comprise at least a functional part of a nucleic acid sequence encoding an adenovirus E1 region in expressible format. In even more preferred embodiments, the host cells are derived from a human retina and immortalized

with nucleic acids comprising adenoviral E1 sequences, such as 911 cells or the cell line deposited at the European Collection of Cell Cultures (ECACC), CAMR, Salisbury, Wiltshire SP4 OJG, Great Britain on 29 Feb. 1996 under number 96022940 and marketed under the trademark PER.C6® (PER.C6® is a registered trademark of Crucell Holland B.V.). For the purposes of this application "PER.C6" refers to cells deposited under number 96022940 or ancestors, passages up-stream or downstream as well as descendants from ancestors of deposited cells, as well as derivatives of any of the foregoing. Production of recombinant proteins in host cells can be performed according to methods well-known in the art. The use of the cells marketed under the trademark PER.C6® as a production platform for proteins of interest has been described in WO 00/63403 the disclosure of which is incorporated herein by reference in its entirety.

A method of producing the binding molecule is an additional part hereof. The method comprises the steps of a) culturing a host under conditions conducive to the expression of the binding molecule, and b) optionally, recovering the expressed binding molecule. The expressed binding molecules or immunoconjugates can be recovered from the cell free extract, but preferably they are recovered from the culture medium. This method of producing can also be used to make functional variants of the binding molecules and/or immunoconjugates hereof. Methods to recover proteins, such as binding molecules, from cell free extracts or culture medium are well-known to the person skilled in the art. Binding molecules, functional variants and/or immunoconjugates as obtainable by the above-described method are also a part hereof.

Alternatively, next to the expression in hosts, such as host cells, the binding molecules and immunoconjugates hereof can be produced synthetically by conventional peptide synthesizers or in cell-free translation systems using RNA nucleic acid derived from DNA molecules according to the invention. Binding molecules and immunoconjugates as obtainable by the above described synthetic production methods or cell-free translation systems are also a part hereof.

In yet another embodiment, binding molecules hereof can also be produced in transgenic, non-human, mammals such as inter alia rabbits, goats or cows, and secreted into for instance the milk thereof.

In yet another alternative embodiment, the binding molecules hereof, preferably human binding molecules specifically binding to *enterococci* or a fragment thereof, may be generated by transgenic non-human mammals, such as for instance transgenic mice or rabbits, that express human immunoglobulin genes. Preferably, the transgenic non-human mammals have a genome comprising a human heavy chain transgene and a human light chain transgene encoding all or a portion of the human binding molecules as described above. The transgenic non-human mammals can be immunized with a purified or enriched preparation of *enterococci* or a fragment thereof. Protocols for immunizing non-human mammals are well established in the art. See *Using Antibodies: A Laboratory Manual*, Edited by: E. Harlow, D. Lane (1998), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. and *Current Protocols in Immunology*, Edited by: J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober (2001), John Wiley & Sons Inc., New York, the disclosures of which are incorporated herein by reference. Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant, but may also include naked DNA immunizations. In another embodiment, the human binding molecules are produced by B-cells

or plasma cells derived from the transgenic animals. In yet another embodiment, the human binding molecules are produced by hybridomas, which are prepared by fusion of B-cells obtained from the above-described transgenic non-human mammals to immortalized cells. B-cells, plasma cells and hybridomas as obtainable from the above-described transgenic non-human mammals and human binding molecules as obtainable from the above-described transgenic non-human mammals, B-cells, plasma cells and hybridomas are also a part hereof.

In a further aspect, provided are methods of identifying a binding molecule, such as a human binding molecule, e.g. a human monoclonal antibody or fragment thereof, specifically binding to at least two different bacterial organisms or nucleic acid molecules encoding such binding molecules and comprises the steps of: (a) contacting a collection of binding molecules on the surface of replicable genetic packages with a first bacterial organism under conditions conducive to binding, (b) selecting at least once for a replicable genetic package binding to the first bacterial organism, (c) optionally, separating the replicable genetic package binding to the first bacterial organism from replicable genetic packages that do not bind to the first bacterial organism, contacting the separated replicable genetic packages with a second bacterial organism under conditions conducive to binding and selecting at least once for a replicable genetic package binding to the second bacterial organism, and (d) separating and recovering the replicable genetic package binding to the first and/or second bacterial organism from replicable genetic packages that do not bind to the first and/or second bacterial organism. Of course, the above methods extended with selections on third and further bacterial organisms are also part hereof. Another part hereof is a method of identifying a binding molecule, such as a human binding molecule, e.g. a human monoclonal antibody or fragment thereof, specifically binding to an enterococcal species or nucleic acid molecules encoding such a binding molecule. Such a method comprises the same steps as the method mentioned above. A replicable genetic package as used herein can be prokaryotic or eukaryotic and includes cells, spores, yeasts, bacteria, viruses, (bacterio)phage, ribosomes and polysomes. A preferred replicable genetic package is a phage. The binding molecules, such as for instance single chain Fvs, are displayed on the replicable genetic package, i.e. they are attached to a group or molecule located at an exterior surface of the replicable genetic package. The replicable genetic package is a screenable unit comprising a binding molecule to be screened linked to a nucleic acid molecule encoding the binding molecule. The nucleic acid molecule should be replicable either in vivo (e.g., as a vector) or in vitro (e.g., by PCR, transcription and translation). In vivo replication can be autonomous (as for a cell), with the assistance of host factors (as for a virus) or with the assistance of both host and helper virus (as for a phagemid). Replicable genetic packages displaying a collection of binding molecules is formed by introducing nucleic acid molecules encoding exogenous binding molecules to be displayed into the genomes of the replicable genetic packages to form fusion proteins with endogenous proteins that are normally expressed from the outer surface of the replicable genetic packages. Expression of the fusion proteins, transport to the outer surface and assembly results in display of exogenous binding molecules from the outer surface of the replicable genetic packages.

The selection step(s) in the methods can be performed with bacterial organisms that are live and still infective or inactivated. Inactivation of bacterial organism may be performed by bacterial inactivation methods well-known to the skilled

artisan such as inter alia treatment with low pH, i.e. pH 4 for 6 hours to 21 days; treatment with organic solvent/detergent, i.e. addition of organic solvents and detergents (Triton X-100 or Tween-80) to the bacterium; UV/light irradiation; gamma-irradiation; and treatment with relevant antibiotics. Methods to test, if a bacterial organism is still alive, infective and/or viable or partly or completely inactivated are well-known to the person skilled in the art. The bacterial organisms used in the above method may be non-isolated, e.g. present in serum and/or blood of an infected individual. The bacterial organisms used may also be isolated as discrete colonies after overnight culture at 37° C. on a suitable medium such as sheep blood agar.

In certain embodiments, the first and/or second bacterial organisms are in suspension when contacted with the replicable genetic packages. Alternatively, they may also be coupled to a carrier when contact takes place. In another embodiment the first and second bacterial organisms are from a different bacterial family, e.g. the first is from a Gram-negative bacterium and the second is from a Gram-positive bacterium. This way, binding molecules capable of specifically binding to Gram-positive and Gram-negative bacteria can be found. Preferably, the first and second bacterial organisms are both Gram-positive bacteria. The first and second bacterial organism can both be *enterococci*. In one embodiment the first and second bacterial organism are different strains from the same bacterial species, e.g. an *Enterococcus* species such as *E. faecalis* or *E. faecium*. This way, species-specific binding molecules can be found that are capable of specifically binding to different strains within one species. In another embodiment, the first and second bacterial organisms are each a member of a different *Enterococcus* species, e.g. the first and second *Enterococcus* species are selected from the group consisting of *E. faecalis* and *E. faecium*. This way, binding molecules capable of specifically binding to different species within one bacterial genus can be found.

Alternatively, the selection step may be performed in the presence of a fragment of the bacterial organisms such as e.g. cell membrane preparations, cell membrane preparations that have been enzymatically treated to remove proteins (e.g. with protease K), cell membrane preparations that have been enzymatically treated to remove carbohydrate moieties (e.g. with periodate), recombinant proteins or polysaccharides. In yet another embodiment, the selection step may be performed in the presence of one or more proteins or peptides or polypeptides derived from the bacterial organisms, fusion proteins comprising these proteins or peptides or polypeptides, and the like. Extracellularly exposed parts of these proteins can also be used as selection material. The live or inactivated bacterial organisms or fragments thereof may be immobilized to a suitable material before use. Alternatively, live or inactivated bacteria in suspension are used. In an embodiment the selection can be performed on different materials derived from bacterial organisms. For instance, the first selection round can be performed on live or inactivated bacterial organisms in suspension, while the second and third selection round can be performed on recombinant bacterial proteins and polysaccharides, respectively. Of course, other combinations are also contemplated herein. Different bacterial materials can also be used during one selection/panning step. In a further aspect provided are methods wherein the bacterial organisms used in the selection step(s) are derived from the same or different growth phases of the bacteria, e.g. the lag phase, log phase, stationary phase or death phase. This way, e.g. phase-specific anti-bacterial binding molecules may be found. For instance, the first bacterial organism may be an *E. faecalis* in stationary phase, while the second bacterial organism is an *E. faecalis* in

log phase or the first bacterial organism may be an *E. faecalis* in lag phase, while the second bacterial organism is an *E. faecium* in lag phase. Further combinations are well within the reach of the skilled artisan.

Further provided is a method of obtaining a binding molecule specifically binding to at least two different bacterial organisms or a nucleic acid molecule encoding such a binding molecule, wherein the method comprises the steps of a) performing the above described method of identifying binding molecules, and b) isolating from the recovered replicable genetic package the binding molecule and/or the nucleic acid molecule encoding the binding molecule. The collection of binding molecules on the surface of replicable genetic packages can be a collection of scFvs or Fabs. Once a new scFv or Fab has been established or identified with the above-mentioned method of identifying binding molecules or nucleic acid molecules encoding the binding molecules, the DNA encoding the scFv or Fab can be isolated from the bacteria or phages and combined with standard molecular biological techniques to make constructs encoding bivalent scFvs or complete human immunoglobulins of a desired specificity (e.g. IgG, IgA or IgM). These constructs can be transfected into suitable cell lines and complete human monoclonal antibodies can be produced (see Huls et al., 1999; Boel et al., 2000).

The preferred replicable genetic package is a phage. Phage display methods for identifying and obtaining (human) binding molecules, e.g. (human) monoclonal antibodies, are by now well-established methods known by the person skilled in the art. They are e.g. described in U.S. Pat. No. 5,696,108; Burton and Barbas, 1994; de Kruif et al., 1995b; and Phage Display: A Laboratory Manual. Edited by: C F Barbas, D R Burton, J K Scott and G J Silverman (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. All these references are herewith incorporated herein in their entirety. For the construction of phage display libraries, collections of human monoclonal antibody heavy and light chain variable region genes are expressed on the surface of bacteriophage, preferably filamentous bacteriophage, particles, in for example single-chain Fv (scFv) or in Fab format (see de Kruif et al., 1995b). Large libraries of antibody fragment-expressing phages typically contain more than 1.0×10^9 antibody specificities and may be assembled from the immunoglobulin V-regions expressed in the B-lymphocytes of immunized- or non-immunized individuals. In a specific embodiment hereof the phage library of binding molecules, preferably scFv phage library, is prepared from RNA isolated from cells obtained from a subject that has been vaccinated against a bacterium, recently vaccinated against an unrelated pathogen, recently suffered from a chronic or acute bacterial infection, e.g. enterococcal infection, or from a healthy individual. RNA can be isolated from inter alia bone marrow or peripheral blood, preferably peripheral blood lymphocytes or on isolated B-cells or even on subpopulations of B-cells. The subject can be an animal vaccinated against a bacterium or an animal that has or has had a bacterial infection. Preferably, the animal is a human subject that has been vaccinated against a bacterium or has or has had a chronic bacterial infection or an acute bacterial infection. Preferably, the human subject has recently recovered from the bacterial infection.

Alternatively, phage display libraries may be constructed from immunoglobulin variable regions that have been partially assembled in vitro to introduce additional antibody diversity in the library (semi-synthetic libraries). For example, in vitro assembled variable regions contain stretches of synthetically produced, randomized or partially randomized DNA in those regions of the molecules that are

important for antibody specificity, e.g. CDR regions. Phage antibodies specific for bacteria such as *enterococci* can be selected from the library by exposing the bacteria or material thereof to a phage library to allow binding of phages expressing antibody fragments specific for the bacteria or material thereof. Non-bound phages are removed by washing and bound phages eluted for infection of *E. coli* bacteria and subsequent propagation. Multiple rounds of selection and propagation are usually required to sufficiently enrich for phages binding specifically to the bacteria or material thereof. If desired, before exposing the phage library to the bacteria or material thereof the phage library can first be subtracted by exposing the phage library to non-target material such as bacteria of a different family, species and/or strain or bacteria in a different growth phase or material of these bacteria. These subtractor bacteria or material thereof can be bound to a solid phase or can be in suspension. Phages may also be selected for binding to complex antigens such as complex mixtures of bacterial proteins or peptides or polypeptides optionally supplemented with bacterial polysaccharides or other bacterial material. Host cells expressing one or more proteins or peptides or polypeptides of bacteria such as *enterococci* may also be used for selection purposes. A phage display method using these host cells can be extended and improved by subtracting non-relevant binders during screening by addition of an excess of host cells comprising no target molecules or non-target molecules that are similar, but not identical, to the target, and thereby strongly enhance the chance of finding relevant binding molecules. Of course, the subtraction may be performed before, during or after the screening with bacterial organisms or material thereof. The process is referred to as the Mabstrac[®] process (Mabstrac[®] is a registered trademark of Crucell Holland B.V., see also U.S. Pat. No. 6,265,150 which is incorporated herein by reference).

Also provided are methods of obtaining a binding molecule potentially having killing activity against a bacterial organism, preferably at least two different bacterial organisms, wherein the method comprises the steps of (a) performing the method of obtaining a binding molecule specifically binding to at least two different bacterial organisms or a nucleic acid molecule encoding such a binding molecule as described above, and (b) verifying if the binding molecule isolated has killing activity against the bacterial organism, preferably the at least two different bacterial organisms. Assays for verifying if a binding molecule has killing activity such as opsonic activity are well-known in the art (see for instance Manual of Molecular and Clinical Laboratory Immunology, 7th Edition). In a further embodiment, the binding molecule is also tested for any other activity. Other useful activities are mentioned above.

Also disclosed is a binding molecule having killing activity against at least two, preferably at least three or more, different bacterial organisms, such as e.g. *enterococci*, and being obtainable by the methods as described above. A pharmaceutical composition comprising the binding molecule, the pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient is also an aspect hereof. Pharmaceutically acceptable excipients are well-known to the skilled person. The pharmaceutical composition according to the invention may further comprise at least one other therapeutic agent. Suitable agents are also well-known to the skilled artisan.

Also disclosed are compositions comprising at least one binding molecule preferably a human monoclonal antibody hereof, at least one functional variant thereof, at least one immunoconjugate according to the invention or a combina-

tion thereof. In addition to that, the compositions may comprise inter alia stabilizing molecules, such as albumin or polyethylene glycol, or salts. The salts used may be salts that retain the desired biological activity of the binding molecules and do not impart any undesired toxicological effects. If necessary, the human binding molecules hereof may be coated in or on a material to protect them from the action of acids or other natural or non-natural conditions that may inactivate the binding molecules.

Also disclosed are compositions comprising at least one nucleic acid molecule as defined herein. The compositions may comprise aqueous solutions such as aqueous solutions containing salts (e.g., NaCl or salts as described above), detergents (e.g., SDS) and/or other suitable components.

Also disclosed are pharmaceutical compositions comprising at least one binding molecule such as a human monoclonal antibody hereof (or functional fragment or variant thereof), at least one immunoconjugate hereof, at least one composition hereof, or combinations thereof. The pharmaceutical composition hereof further comprises at least one pharmaceutically acceptable excipient.

In certain embodiments, the pharmaceutical compositions may comprise two or more binding molecules that have killing activity against a bacterial organism, e.g. an *Enterococcus* species. In an embodiment, the binding molecules exhibit synergistic killing activity, when used in combination. In other words, the compositions comprise at least two binding molecules having killing activity, characterized in that the binding molecules act synergistically in killing a bacterial organism such as e.g. an *Enterococcus* species. As used herein, the term "synergistic" means that the combined effect of the binding molecules when used in combination is greater than their additive effects when used individually. The synergistically acting binding molecules may bind to different structures on the same or distinct fragments of the bacterial organism. In an embodiment the binding molecules acting synergistically in killing a bacterial organism may also be capable of killing other bacterial organisms synergistically. A way of calculating synergy is by means of the combination index. The concept of the combination index (CI) has been described by Chou and Talalay, 1984. The two or more binding molecules having synergistic activity have distinct modes of action. For instance a first binding molecule may have opsonizing activity, while the second binding molecule has another activity increasing/augmenting/enhancing phagocytosis or a first binding molecule may have intrinsic (killing) activity, e.g. reduce or inhibit bacterial growth or directly kill bacteria, while the second binding molecule increases the sensitivity of bacteria to antibiotic treatment. Other combinations are contemplated herein.

A pharmaceutical composition hereof can further comprise at least one other therapeutic, prophylactic and/or diagnostic agent. Preferably, the pharmaceutical composition comprises at least one other prophylactic and/or therapeutic agent. Preferably, the further therapeutic and/or prophylactic agents are agents capable of preventing and/or treating a bacterial, e.g. enterococcal, infection and/or a condition resulting from such an infection. Therapeutic and/or prophylactic agents include, but are not limited to, anti-bacterial agents. Such agents can be binding molecules, small molecules, organic or inorganic compounds, enzymes, polynucleotide sequences, anti-microbial peptides, etc. Other agents that are currently used to treat patients infected with bacterial infections such as enterococcal infections are antibiotics such as vancomycin, teicoplanin, synergistic combinations including ampicillin or vancomycin and an aminoglycoside or sulbactam, penicillins including extended spectrum penicillins, carbapenems, mac-

rolides, quinolones, tetracyclines, chloramphenicol, daptomycin, linezolid, quinupristin/dalfopristin. These can be used in combination with the binding molecules hereof. Agents capable of preventing and/or treating an infection with bacteria and/or a condition resulting from such an infection that are in the experimental phase might also be used as other therapeutic and/or prophylactic agents useful herein.

The binding molecules or pharmaceutical compositions hereof may be tested in suitable animal model systems prior to use in humans. Such animal model systems include, but are not limited to, murine sepsis and peritonitis models, rat sepsis and endocarditis models, and rabbit endocarditis models.

Typically, pharmaceutical compositions are sterile and stable under the conditions of manufacture and storage. The binding molecules, immunoconjugates, nucleic acid molecules or compositions hereof can be in powder form for reconstitution in the appropriate pharmaceutically acceptable excipient before or at the time of delivery. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Alternatively, the binding molecules, immunoconjugates, nucleic acid molecules or compositions hereof can be in solution and the appropriate pharmaceutically acceptable excipient can be added and/or mixed before or at the time of delivery to provide a unit dosage injectable form. Preferably, the pharmaceutically acceptable excipient used herein is suitable to high drug concentration, can maintain proper fluidity and, if necessary, can delay absorption.

The choice of the optimal route of administration of the pharmaceutical compositions will be influenced by several factors including the physico-chemical properties of the active molecules within the compositions, the urgency of the clinical situation and the relationship of the plasma concentrations of the active molecules to the desired therapeutic effect. For instance, if necessary, the binding molecules hereof can be prepared with carriers that will protect them against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can inter alia be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Furthermore, it may be necessary to coat the binding molecules with, or co-administer the binding molecules with, a material or compound that prevents the inactivation of the human binding molecules. For example, the binding molecules may be administered to a subject in an appropriate carrier, for example, liposomes or a diluent.

The routes of administration can be divided into two main categories, oral and parenteral administration. The preferred administration route is intravenous.

Oral dosage forms can be formulated inter alia as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard capsules, soft gelatin capsules, syrups or elixirs, pills, dragees, liquids, gels, or slurries. These formulations can contain pharmaceutically acceptable excipients including, but not limited to, inert diluents, granulating and disintegrating agents, binding agents, lubricating agents, preservatives, coloring, flavoring or sweetening agents, vegetable or mineral oils, wetting agents, and thickening agents.

The pharmaceutical compositions hereof can also be formulated for parenteral administration. Formulations for parenteral administration can be inter alia in the form of

aqueous or non-aqueous isotonic sterile non-toxic injection or infusion solutions or suspensions. The solutions or suspensions may comprise agents that are non-toxic to recipients at the dosages and concentrations employed such as 1,3-butane-
diol, Ringer's solution, Hank's solution, isotonic sodium
chloride solution, oils, fatty acids, local anesthetic agents,
preservatives, buffers, viscosity or solubility increasing
agents, water-soluble antioxidants, oil-soluble antioxidants,
and metal chelating agents.

In a further aspect, the binding molecules such as human
monoclonal antibodies (functional fragments and variants
thereof), immunoconjugates, compositions, or pharmaceuti-
cal compositions hereof can be used as a medicament. So, a
method of treatment and/or prevention of a bacterial (Gram-
positive and/or Gram-negative), e.g. an enterococcal, infec-
tion using the binding molecules, immunoconjugates, com-
positions, or pharmaceutical compositions hereof is another
part hereof. The above-mentioned molecules can inter alia be
used in the diagnosis, prophylaxis, treatment, or combination
thereof, of a bacterial infection. Important clinical infections
caused by *enterococci* include, but are not limited to, urinary
tract infections, intra-abdominal, pelvic and soft tissue infec-
tions, bacteraemia, bacterial endocarditis, diverticulitis, men-
ingitis, peritonitis, osteomyelitis, septic arthritis, abscesses,
wound infections and pneumonia. They are suitable for treat-
ment of yet untreated patients suffering from a bacterial infec-
tion and patients who have been or are treated for a bacterial
infection. They may be used for patients such as hospitalized
infants, infants born prematurely, burn victims, elderly
patients, immunocompromised patients such as those receiv-
ing chemotherapy, immunosuppressed patients such as
those receiving transplanted organs, immunodeficient
patients, patient undergoing an invasive procedure, and health
care workers. Each administration may protect against further
infection by the bacterial organism for up to three or four
weeks and/or will retard the onset or progress of the symp-
toms associated with the infection. The binding molecules
hereof may also increase the effectiveness of existing antibi-
otic treatment by increasing the sensitivity of the bacterium to
the antibiotic, may stimulate the immune system to attack the
bacterium in ways other than through opsonization. This acti-
vation may result in long lasting protection to the infection
bacterium. Furthermore, the binding molecules hereof may
directly inhibit the growth of the bacterium or inhibit viru-
lence factors required for its survival during the infection.

The above-mentioned molecules or compositions may be
employed in conjunction with other molecules useful in diag-
nosis, prophylaxis and/or treatment. They can be used in
vitro, ex vivo or in vivo. For instance, the binding molecules
such as human monoclonal antibodies (or functional variants
thereof), immunoconjugates, compositions or pharmaceuti-
cal compositions hereof can be co-administered with a vac-
cine against the bacterial organism (if available). Alternat-
ively, the vaccine may also be administered before or after
administration of the molecules hereof. Instead of a vaccine,
anti-bacterial agents can also be employed in conjunction
with the binding molecules hereof. Suitable anti-bacterial
agents are mentioned above.

The molecules are typically formulated in the composi-
tions and pharmaceutical compositions hereof in a therapeu-
tically or diagnostically effective amount. Alternatively, they
may be formulated and administered separately. For instance
the other molecules such as the anti-bacterial agents may be
applied systemically, while the binding molecules hereof
may be applied intrathecally or intraventricularly.

Dosage regimens can be adjusted to provide the optimum
desired response (e.g., a therapeutic response). A suitable

dosage range may for instance be 0.1-100 mg/kg body
weight, preferably 0.5-15 mg/kg body weight. Furthermore,
for example, a single bolus may be administered, several
divided doses may be administered over time or the dose may
be proportionally reduced or increased as indicated by the
exigencies of the therapeutic situation. The molecules and
compositions according to the invention are preferably ster-
ile. Methods to render these molecules and compositions
sterile are well-known in the art. The other molecules useful
in diagnosis, prophylaxis and/or treatment can be adminis-
tered in a similar dosage regimen as proposed for the binding
molecules hereof. If the other molecules are administered
separately, they may be administered to a patient prior to (e.g.,
2 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45
minutes, 60 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10
hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22
hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 7 days, 2
weeks, 4 weeks or 6 weeks before), concomitantly with, or
subsequent to (e.g., 2 minutes, 5 minutes, 10 minutes, 15
minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 4
hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16
hours, 18 hours, 20 hours, 22 hours, 24 hours, 2 days, 3 days,
4 days, 5 days, 7 days, 2 weeks, 4 weeks or 6 weeks after) the
administration of one or more of the human binding mol-
ecules or pharmaceutical compositions hereof. The exact dos-
ing regimen is usually sorted out during clinical trials in
human patients.

Human binding molecules and pharmaceutical composi-
tions comprising the human binding molecules are particu-
larly useful, and often preferred, when to be administered to
human beings as in vivo therapeutic agents, since recipient
immune response to the administered antibody will often be
substantially less than that occasioned by administration of a
monoclonal murine, chimeric or humanized binding mol-
ecule.

In another aspect, the invention concerns the use of the
binding molecules such as killing human monoclonal anti-
bodies (functional fragments and variants thereof), immuno-
conjugates, nucleic acid molecules, compositions or pharma-
ceutical compositions according to the invention in the
preparation of a medicament for the diagnosis, prophylaxis,
treatment, or combination thereof, of a bacterial (Gram-posi-
tive and/or Gram-negative), e.g. enterococcal infection.

Next to that, kits comprising at least one binding molecule
such as a killing human monoclonal antibody (functional
fragments and variants thereof), at least one immunoconju-
gate, at least one nucleic acid molecule, at least one compo-
sition, at least one pharmaceutical composition, at least one
vector, at least one host according to the invention or a com-
bination thereof are also a part hereof. Optionally, the above-
described components of the kits hereof are packed in suitable
containers and labeled for diagnosis, prophylaxis and/or
treatment of the indicated conditions. The above-mentioned
components may be stored in unit or multi-dose containers as
an aqueous, preferably sterile, solution or as a lyophilized,
preferably sterile, formulation for reconstitution. The con-
tainers may be formed from a variety of materials such as
glass or plastic and may have a sterile access port (for
example the container may be an intravenous solution bag or
a vial having a stopper pierceable by a hypodermic injection
needle). The kit may further comprise more containers com-
prising a pharmaceutically acceptable buffer. It may further
include other materials desirable from a commercial and user
standpoint, including other buffers, diluents, filters, needles,
syringes, culture medium for one or more of the suitable hosts
and, possibly, even at least one other therapeutic, prophylactic
or diagnostic agent. Associated with the kits can be instruc-

tions customarily included in commercial packages of therapeutic, prophylactic or diagnostic products, that contain information about for example the indications, usage, dosage, manufacture, administration, contra-indications and/or warn- 5 ings concerning the use of such therapeutic, prophylactic or diagnostic products.

The binding molecules hereof may also be used to coat medical devices or polymeric biomaterials.

Further described is a method of detecting a bacterial organism (Gram-positive and/or Gram-negative) in a sample, 10 wherein the method comprises the steps of (a) contacting a sample with a diagnostically effective amount of a binding molecule (functional fragments and variants thereof) or an immunoconjugate according to the invention, and (b) deter- 15 mining whether the binding molecule or immunoconjugate specifically binds to a molecule of the sample. Preferably, the method is used to detect an *Enterococcus* in a sample. The sample may be a biological sample including, but not limited to blood, serum, urine, tissue or other biological material from (potentially) infected subjects, or a non-biological 20 sample such as water, drink, etc. The (potentially) infected subjects may be human subjects, but also animals that are suspected as carriers of such a bacterial organism might be tested for the presence of the organism using the human binding molecules or immunoconjugates hereof. The sample 25 may first be manipulated to make it more suitable for the method of detection. Manipulation means inter alia treating the sample suspected to contain and/or containing the bacterial organism in such a way that the organism will disintegrate into antigenic components such as proteins, peptides or 30 polypeptides or other antigenic fragments. Preferably, the human binding molecules or immunoconjugates hereof are contacted with the sample under conditions which allow the formation of an immunological complex between the human binding molecules and the bacterial organism or antigenic 35 components thereof that may be present in the sample. The formation of an immunological complex, if any, indicating the presence of the bacterial organism in the sample, is then detected and measured by suitable means. Such methods 40 include, inter alia, homogeneous and heterogeneous binding immunoassays, such as radio-immunoassays (RIA), ELISA, immunofluorescence, immunohistochemistry, FACS, BIA-CORE and Western blot analyses.

Preferred assay techniques, especially for large-scale clinical screening of patient sera and blood and blood-derived 45 products are ELISA and Western blot techniques. ELISA tests are particularly preferred. For use as reagents in these assays, the binding molecules or immunoconjugates hereof are conveniently bonded to the inside surface of microtiter wells. The binding molecules or immunoconjugates hereof 50 may be directly bonded to the microtiter well. However, maximum binding of the binding molecules or immunoconjugates hereof to the wells might be accomplished by pre-treating the wells with polylysine prior to the addition of the binding molecules or immunoconjugates hereof. Further- 55 more, the binding molecules or immunoconjugates hereof may be covalently attached by known means to the wells. Generally, the binding molecules or immunoconjugates are used between 0.01 to 100 µg/ml for coating, although higher as well as lower amounts may also be used. Samples are then 60 added to the wells coated with the binding molecules or immunoconjugates hereof.

Furthermore, the binding molecules hereof can be used to identify specific binding structures of a bacterial organism e.g. an *Enterococcus*. The binding structures can be epitopes 65 on proteins and/or polypeptides. They can be linear, but also structural and/or conformational. In one embodiment, the

binding structures can be analyzed by means of PEPSCAN analysis (see inter alia WO 84/03564, WO 93/09872, Slootstra et al., 1996). Alternatively, a random peptide library comprising peptides from a protein of a bacterial organism can be screened for peptides capable of binding to the binding 5 molecules hereof. The binding structures/peptides/epitopes found can be used as vaccines and for the diagnosis of bacterial infections. In case fragments other than proteins and/or polypeptides are bound by the binding molecules binding 10 structures can be identified by mass spectrometry, high performance liquid chromatography and nuclear magnetic resonance.

In a further aspect, provided is a method of screening a binding molecule (or a functional fragment or variant thereof) 15 for specific binding to the same epitope of a bacterial organism (Gram-positive and/or Gram-negative), e.g. *Enterococcus*, as the epitope bound by a human binding molecule hereof, wherein the method comprises the steps of (a) contacting a binding molecule to be screened, a binding molecule 20 hereof and a bacterial organism or fragment thereof, (b) measure if the binding molecule to be screened is capable of competing for specifically binding to the bacterial organism or fragment thereof with the binding molecule hereof. In a further step it may be determined, if the screened binding 25 molecules that are capable of competing for specifically binding to the bacterial organism or fragment thereof have killing activity, e.g. opsonic activity. A binding molecule that is capable of competing for specifically binding to the bacterial organism or a fragment thereof with the binding molecule 30 hereof is another part hereof. In the above-described screening method, "specifically binding to the same epitope" also contemplates specific binding to substantially or essentially the same epitope as the epitope bound by the a binding molecule hereof. The capacity to block, or compete with, the 35 binding of the binding molecules hereof to the bacterial organism typically indicates that a binding molecule to be screened binds to an epitope or binding site on the bacterial organism that structurally overlaps with the binding site on the bacterial organism that is immunospecifically recognized 40 by the binding molecules hereof. Alternatively, this can indicate that a binding molecule to be screened binds to an epitope or binding site which is sufficiently proximal to the binding site immunospecifically recognized by the binding molecules hereof to sterically or otherwise inhibit binding of the binding 45 molecules hereof to the bacterial organism.

In general, competitive inhibition is measured by means of an assay, wherein an antigen composition, i.e. a composition comprising a bacterial organism or fragments thereof, is admixed with reference binding molecules, i.e. the binding 50 molecules hereof, and binding molecules to be screened. Usually, the binding molecules to be screened are present in excess. Protocols based upon ELISAs and Western blotting are suitable for use in such simple competition studies. By using species or isotype secondary antibodies one will be able 55 to detect only the bound reference binding molecules, the binding of which will be reduced by the presence of a binding molecule to be screened that recognizes substantially the same epitope. In conducting a binding molecule competition study between a reference binding molecule and any binding 60 molecule to be screened (irrespective of species or isotype), one may first label the reference binding molecule with a detectable label, such as, e.g., biotin, an enzymatic, a radioactive or other label to enable subsequent identification. Binding molecules identified by these competition assays 65 ("competitive binding molecules" or "cross-reactive binding molecules") include, but are not limited to, antibodies, antibody fragments and other binding agents that bind to an

epitope or binding site bound by the reference binding molecule, i.e. a binding molecule hereof, as well as antibodies, antibody fragments and other binding agents that bind to an epitope or binding site sufficiently proximal to an epitope bound by the reference binding molecule for competitive binding between the binding molecules to be screened and the reference binding molecule to occur. Preferably, competitive binding molecules hereof will, when present in excess, inhibit specific binding of a reference binding molecule to a selected target species by at least 10%, preferably by at least 25%, more preferably by at least 50%, and most preferably by at least 75%-90% or even greater. The identification of one or more competitive binding molecules that bind to about, substantially, essentially or at the same epitope as the binding molecules hereof is a straightforward technical matter. As the identification of competitive binding molecules is determined in comparison to a reference binding molecule, i.e. a binding molecule hereof, it will be understood that actually determining the epitope to which the reference binding molecule and the competitive binding molecule bind is not in any way required in order to identify a competitive binding molecule that binds to the same or substantially the same epitope as the reference binding molecule.

EXAMPLES

The following illustrative Examples further describe the disclosure.

Example 1

Construction of scFv Phage Display Libraries Using RNA Extracted from Donors Screened for Opsonic Activity

Samples of blood were taken from donors reporting a recent gram-positive bacterial infection as well as healthy adults between 25-50 years of age. Peripheral blood leukocytes were isolated by centrifugation and the blood serum was saved and frozen at -80°C . Donor serum was screened for killing activity using an opsonophagocytic killing assay (Huebner et al. 1999) and compared to normal rabbit serum. Sera from donors having phagocytic activity greater than the normal serum were chosen to use for the generation of phage display libraries. Total RNA was prepared from the peripheral blood leukocytes of these donors using organic phase separation and subsequent ethanol precipitation. The obtained RNA was dissolved in RNase free water and the concentration was determined by OD 260 nm measurement. Thereafter, the RNA was diluted to a concentration of 100 ng/ μl . Next, 1 μg of RNA was converted into cDNA as follows: To 10 μl total RNA, 13 μl DEPC-treated ultrapure water and 1 μl random hexamers (500 ng/ μl) were added and the obtained mixture was heated at 65°C . for 5 minutes and quickly cooled on wet-ice. Then, 8 μl 5 \times First-Strand buffer, 2 μl dNTP (10 mM each), 2 μl DTT (0.1 M), 2 μl RNase-inhibitor (40 U/ μl) and 2 μl SuperscriptTM III MMLV reverse transcriptase (200 U/ μl) were added to the mixture, incubated at room temperature for 5 minutes and incubated for 1 hour at 50°C . The reaction was terminated by heat inactivation, i.e. by incubating the mixture for 15 minutes at 75°C . The obtained cDNA products were diluted to a final volume of 200 μl with DEPC-treated ultrapure water. The OD 260 nm of a 50 times diluted solution (in 10 mM Tris buffer) of the dilution of the obtained cDNA products was used to determine the cDNA concentration. For each donor 5 to 10 μl of the diluted cDNA products were used as template for PCR amplification of the immunoglobulin gamma heavy chain family and kappa or lambda light chain sequences using specific oligonucleotide primers (see Tables

1-7). In addition, for one donor PCR amplification of the immunoglobulin mu heavy chain family and kappa or lambda light chain sequences was carried out. PCR reaction mixtures contained, besides the diluted cDNA products, 25 pmol sense primer and 25 pmol anti-sense primer in a final volume of 50 μl of 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl_2 , 250 μM dNTPs and 1.25 units Taq polymerase. In a heated-lid thermal cycler having a temperature of 96°C ., the mixtures obtained were quickly melted for 2 minutes, followed by 30 cycles of: 30 seconds at 96°C ., 30 seconds at 55°C . or 60°C . and 60 seconds at 72°C . Finally, the samples were incubated 10 minutes at 72°C . and refrigerated at 4°C . until further use.

In a first round amplification, each of 18 light chain variable region sense primers (twelve for the lambda light chain (see Table 1; the HuVL1A-Back, HuVL1B-Back and HuVL1C-Back sense primers were mixed to equimolarity before use, as well as the HuVL9-Back and HuVL10-Back sense primers) and six for the kappa light chain (see Table 2)) were combined with an anti-sense primer recognizing the C-kappa constant region called HuCK-FOR 5'-ACACTCTC-CCCTGTTGAAGCTCTT-3' (see SEQ ID NO:121) or C-lambda constant region HuCL2-FOR 5'-TGAACATTCTGTAGGGGCCACTG-3' (see SEQ ID NO:122) and HuCL7-FOR 5'-AGAGCATTCTGCAGGGGCCACTG-3' (see SEQ ID NO:123) (the HuCL2-FOR and HuCL7-FOR anti-sense primers were mixed to equimolarity before use), yielding 15 products of about 650 base pairs. These products were purified on agarose gel and isolated from the gel using Qiagen gel-extraction columns. $\frac{1}{10}$ of each of the isolated products was used in an identical PCR reaction as described above using eighteen sense primers, whereby each lambda light chain sense primer was combined with one of the three J-lambda-region specific anti-sense primers and each kappa light chain sense primer was combined with one of the five J-kappa-region specific anti-sense primers (see Table 3; the HuVL1A-Back-SAL, HuVL1B-Back-SAL and HuVL1C-Back-SAL sense primers were mixed to equimolarity before use, as well as the HuVL9-Back-SAL and HuVL10-Back-SAL sense primers). The sense primers used in the second amplification were the same primers as used in the first amplification, but extended with restriction sites (see Table 3) to enable directed cloning in the phage display vector PDV-006 (see SEQ ID NO:124). This resulted in 57 products of approximately 400 base pairs that were pooled as shown in Table 4 to maintain the natural distribution of the different J segments and light chain families within the library and not to over or under represent certain families. The pooled products were purified using Qiagen PCR purification columns. In the next step, 3 μg of pooled products and 100 μg PDV-006 vector were digested with SalI and NotI and purified from gel. Thereafter, a ligation was performed overnight at 16°C . as follows. To 500 ng PDV-006 vector either 35, 70 or 140 ng pooled products were added in a total volume of 50 μl ligation mix containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl_2 , 10 mM DTT, 1 mM ATP, 25 $\mu\text{g}/\text{ml}$ BSA and 2.5 μl T4 DNA Ligase (400 U/ μl). The ligation mixes were purified by phenol/chloroform extraction, followed by a chloroform extraction and ethanol precipitation, methods well-known to the skilled artisan. The DNA obtained was dissolved in 50 μl 10 mM Tris-HCl pH8.5 and per ligation mix 1 or 2 μl was electroporated into 40 μl of TG1 competent *E. coli* bacteria according to the manufacturer's protocol (Stratagene). Transformants were grown overnight at 37°C . on 2TY agar supplemented with 50 $\mu\text{g}/\text{ml}$ ampicillin and 4.5% glucose. Colonies were counted to determine the optimal vector to insert ratio. From the ligation mix with the optimal ratio, multiple 1 or 2 μl aliquots were electroporated as above and transformants

were grown overnight at 37° C., typically yielding ~10⁷ colonies. A (sub)library of variable light chain regions was obtained by scraping the transformants from the agar plates. This (sub)library was directly used for plasmid DNA preparation using a Qiagen™ QIAfilter MAXI prep kit.

Heavy chain immunoglobulin sequences were amplified from the same cDNA preparations in a similar two round PCR procedure and identical reaction parameters as described above for the light chain regions with the proviso that the primers depicted in Tables 5 and 6 were used. The first amplification was performed using a set of eight sense directed primers (see Table 5; the HuVH1B/7A-Back and HuVH1C-Back sense primers were mixed to equimolarity before use) each combined with an IgG specific constant region anti-sense primer called HuCIgG 5'-GTC CAC CTT GGT GTT GCT GGG CTT-3' (SEQ ID NO:125) yielding seven products of about 650 base pairs. For one donor an IgM specific constant region anti-sense primer called HuCIgM 5'-TGG AAG AGG CAC GTT CTT TTC TTT-3' (SEQ ID NO:126) was used instead of primer HuCIgG. The products were purified on agarose gel and isolated from the gel using Qiagen gel-extraction columns. 1/10 of each of the isolated products was used in an identical PCR reaction as described above using eight sense primers, whereby each heavy chain sense primer was combined with one of the four JH-region specific anti-sense primers (see Table 6; the HuVH1B/7A-Back-Sfi and HuVH1C-Back-Sfi sense primers were mixed to equimolarity before use). The sense primers used in the second round were the same primers as used in the first amplification, but extended with restriction sites (see Table 6) to enable directed cloning in the light chain (sub)library vector. This resulted in 28 products of approximately 400 base pairs that were pooled as shown in Table 7 to maintain the natural distribution of the different J segments and heavy chain families within the library and not to over or under represent certain families. The pooled products were purified using Qiagen PCR purification columns. Next, 3 µg of purified products was digested with SfiI and XhoI and ligated in the light chain (sub)library vector, which was cut with the same restriction enzymes, using the same ligation procedure and volumes as described above for the light chain (sub)library. Ligation mix purification and subsequent transformation of the resulting definitive library was also performed as described above for the light chain (sub)library. All bacteria, typically ~10⁷, were harvested in 2TY culture medium containing 50 µg/ml ampicillin and 4.5% glucose, mixed with glycerol to 15% (v/v) and frozen in 1.5 ml aliquots at -80° C. Rescue and selection of each library were performed as described below. The various libraries were named GPB-05-M01, GPB-05-G01, GPB-05-G02, GPB-05-G03, GPB-05-G04 and GPB-05-G05. Two other libraries, RAB-03-G01 and RAB-04-G01, were constructed using a method similar to the procedure above, as described previously in international patent application WO 2005/118644.

Example 2

Construction of Scfv Phage Display Libraries Using RNA Extracted from Memory B Cells

Peripheral blood was collected from normal healthy donors, convalescent donors or vaccinated donors by venapuncture using EDTA anti-coagulation sample tubes. A blood sample (45 ml) was diluted twice with PBS and 30 ml aliquots were underlaid with 10 ml Ficoll-Hypaque (Pharmacia) and centrifuged at 900×g for 20 minutes at room temperature without breaks. The supernatant was removed carefully to just above the white layer containing the lympho-

cytic and thrombocytic fraction. Next, this layer was carefully removed (~10 ml), transferred to a fresh 50 ml tube and washed three times with 40 ml PBS and spun at 400×g for 10 minutes at room temperature to remove thrombocytes. The obtained pellet containing lymphocytes was resuspended in RPMI medium containing 2% FBS and the cell number was determined by cell counting. Approximately 1×10⁸ lymphocytes were stained for fluorescent cell sorting using CD24, CD27 and surface IgM as markers for the isolation of switched and IgM memory B cells. A Becton Dickinson Digital Vantage apparatus set in Yield Mode was used for physical memory B cell sorting and isolation. Lymphocytes were gated as the small compact population from the FSC/SSC window. Memory B cells (CD24+/CD27+) were subsequently separated from naive B cells (CD24+/CD27-) and memory T cells (CD24-/CD27+). In a next step, IgM memory B cells (IgM+) were separated from switch memory B cells (IgM-) using IgM expression. In this step IgM memory B cells and switch memory B cells were sorted in separate sample tubes. 1×10⁵ to 1×10⁶ cells of each population were collected in DMEM/50% FBS and after completion of the sort they were each centrifuged at 400×g for 10 minutes. The sorted IgM memory B cells were then used as starting material for library construction according to the method described in Example 1, using primer HuCIgM in the first round amplification of heavy chain immunoglobulin sequences. The various libraries were named MEM-05-M01, MEM-05-M02, MEM-05-M03, MEM-05-M04, MEM-05-M05, MEM-05-M06, MEM-05-M07, MEM-05-M08, MEM-05-M09 and MEM-05-M10.

Example 3

Selection of Phages Carrying Single Chain Fv Fragments Specifically Binding to *Enterococci*

Antibody fragments were selected using antibody phage display libraries, general phage display technology and MAbstract® technology, essentially as described in U.S. Pat. No. 6,265,150 and in WO 98/15833 (both of which are incorporated by reference herein). The antibody phage libraries used were screened and donor libraries prepared as described in Example 1 and IgM memory libraries prepared as described in Example 2. The methods and helper phages as described in WO 02/103012 (incorporated by reference herein) were used herein. For identifying phage antibodies recognizing *enterococci*, phage selection experiments were performed using live bacteria in suspension or bacteria immobilized in immunotubes. Strains used are described in Table 8. All phage antibodies were isolated from selections wherein in at least one step *E. faecalis* 12030 in suspension was used. The phage antibodies called SC05-159 and SC05-166 were originally isolated from selections using immobilized *E. faecalis* 12030, and isolated using *E. faecalis* 12030 in suspension.

Selections using bacteria in suspension were performed as follows. Bacteria were grown overnight at 37° C. on blood agar plates and scraped into PBS containing 2% BSA or 2% ELK at a concentration of 5×10⁹ bacteria/ml and incubated for 30 minutes at room temperature. An aliquot of a phage library (approximately 10¹³ cfu, amplified using CT helper phage (see WO 02/103012)) was blocked in blocking buffer (2% ELK or 2% BSA in PBS) for 0.5-2 hours at room temperature. The blocked phage library was added to the blocked bacterial suspension making a total volume of 1 ml and incubated for 2 hours at room temperature in an end-over-end rotor (5 rpm). The suspension was centrifuged at 6800×g for 3 minutes at room temperature and the supernatant was dis-

carded. Bacteria were washed three to eight times with blocking buffer containing 0.05% (v/v) Tween-20, then three to eight times with blocking buffer to remove unbound phages. Bound phages were eluted from the antigen by incubation with 1 ml of 0.1 M triethylamine for 7 minutes at room temperature in an end-over-end rotor (5 rpm). The suspension was centrifuged at 1700×g for 3 minutes at room temperature and the supernatant was then mixed with 0.5 ml of 1 M Tris-HCl pH 7.5 to neutralize the pH. This mixture was used to infect 5 ml of an XL1-Blue *E. coli* culture that had been grown at 37° C. to an OD 600 nm of approximately 0.3. The phages were allowed to infect the XL1-Blue bacteria for 30 minutes at 37° C. Then, the mixture was centrifuged for 10 minutes at 3200×g at room temperature and the bacterial pellet was resuspended in 0.5 ml 2-trypton yeast extract (2TY) medium. The obtained bacterial suspension was divided over two 2TY agar plates supplemented with tetracyclin, ampicillin and glucose. After overnight incubation of the plates at 37° C., the colonies were scraped from the plates and used to prepare an enriched phage library, essentially as described by De Kruif et al. (1995a) and WO 02/103012. Briefly, scraped bacteria were used to inoculate 2TY medium containing ampicillin, tetracycline and glucose and grown at a temperature of 37° C. to an OD 600 nm of ~0.3. CT helper phages were added and allowed to infect the bacteria after which the medium was changed to 2TY containing ampicillin, tetracycline and kanamycin. Incubation was continued overnight at 30° C. The next day, the bacteria were removed from the 2TY medium by centrifugation after which the phages in the medium were precipitated using polyethylene glycol (PEG) 6000/NaCl. Finally, the phages were dissolved in 2 ml of PBS with 1% bovine serum albumin (BSA), filter-sterilized and used for the next round of selection.

Selections using bacteria immobilized in immunotubes were performed as follows. Bacteria were grown overnight at 37° C. on blood agar plates and scraped into carbonate buffer at a concentration of 5×10^9 bacteria/ml. Two ml was added to a MaxiSorp Nunc-Immuno Tube (Nunc) and incubated overnight at 4° C. in an end-over-end rotor (5 rpm). The tube was emptied and washed three times with PBS. Both the tube and an aliquot of a phage library (approximately 10^{13} cfu, amplified using CT helper phage (see WO 02/103012)) were blocked in blocking buffer (2% ELK, 2% BSA or 1% Protifar in PBS) for 0.5-2 hours at room temperature. The tube was emptied, the blocked phage library was added and the tube was incubated for 2 hours at room temperature in an end-over-end rotor (5 rpm). The tube was washed five to fifteen times with PBS containing 0.1% (v/v) Tween-20, then five to fifteen times with PBS to remove unbound phages. Bound phages were eluted from the antigen by incubation with 1.5 ml of 0.1 M triethylamine or 50 mM Glycine-HCl, pH 2.2 for 10 minutes at room temperature in an end-over-end rotor (5 rpm). The eluted phages were mixed with 0.5 ml of 1 M Tris-HCl pH 7.5 to neutralize the pH. Subsequent infection of XL1-Blue *E. coli* bacteria, growth of infected bacteria and preparation of an enriched phage library was performed as described above for selections using bacteria in suspension.

Typically, two rounds of selections were performed before isolation of individual phage antibodies. Selection could be carried out twice on the same strain of bacteria or different strains could be used sequentially. After the second round of selection, individual *E. coli* colonies were used to prepare monoclonal phage antibodies. Essentially, individual colonies were grown to log-phase and infected with CT or VCSM13 helper phages after which phage antibody production was allowed to proceed overnight. The produced phage

antibodies were PEG/NaCl-precipitated and filter-sterilized and tested in ELISA for binding to *Enterococcus* prepared as described supra.

Example 4

Validation of the Enterococcal Specific Single-chain Phage Antibodies

Selected single-chain phage antibodies that were obtained in the screens described above were validated in ELISA for specific enterococcal binding activity, i.e. binding to one or more enterococcal strains prepared as described supra. 2.5×10^8 bacteria were coated overnight at 4° C. to MaxiSorp™ ELISA plates in 50 μ l 50 mM carbonate buffer, pH 9.6. As negative controls, the complex antigens 2% ELK and 1% BSA both in PBS (pH 7.4) were coated. Wells were washed in PBS containing 0.1% (v/v) Tween-20 and blocked with 300 μ l PBS containing 2% ELK for at least 1 hour at room temperature. The selected single-chain phage antibodies were incubated for 15 minutes in an equal volume of PBS containing 2% ELK to obtain blocked phage antibodies. The plates were emptied and the blocked single-chain phage antibodies were added to the wells. Incubation was allowed to proceed for one hour at room temperature, the plates were washed in PBS containing 0.1% (v/v) Tween-20 and bound phage antibodies were detected using an anti-M13 antibody conjugated to peroxidase. Absorbance at 492 nm was measured using a spectrophotometer. As a control, the procedure was performed simultaneously without single-chain phage antibody and with a negative control single-chain phage antibody directed against West Nile virus envelope protein (SC04-374). As shown in Table 9, the selected phage antibodies called SC05-140, SC05-157, SC05-159, SC05-166, SC05-179, SC05-187, SC06-016, SC06-043, SC06-049, SC06-050, SC06-071, SC06-077, SC06-078, SC06-079, SC06-086, SC06-087, SC06-089, SC06-092, SC06-191, SC06-195, SC06-198, SC06-241, SC06-242, SC06-246, SC06-252, SC06-388, SC06-389, SC06-396, SC06-402, SC06-409, SC06-415, SC06-421, SC06-429 and SC06-432 specifically bound to *Enterococcus faecalis* strain 12030. With the exception of SC05-140 and SC06-421 none of the selected phage antibodies did display any detectable binding to the negative control antigens ELK and BSA.

Example 5

Characterization of the Enterococcal Specific scFvs

From the selected specific single-chain phage antibody (scFv) clones plasmid DNA was obtained and nucleotide sequences were determined according to standard techniques. The nucleotide sequences of the scFvs (including restriction sites for cloning) called SC05-140, SC05-157, SC05-159, SC05-166, SC05-179, SC05-187, SC06-016, SC06-043, SC06-049, SC06-050, SC06-071, SC06-077, SC06-078, SC06-079, SC06-086, SC06-087, SC06-089, SC06-092, SC06-191, SC06-195, SC06-198, SC06-241, SC06-242, SC06-246, SC06-252, SC06-388, SC06-389, SC06-396, SC06-402, SC06-409, SC06-415, SC06-421, SC06-429, and SC06-432 are shown in SEQ ID NO:350, SEQ ID NO:352, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:354, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:356, SEQ ID NO:73, SEQ ID NO:358, SEQ ID NO:75, SEQ ID NO:360, SEQ ID NO:362, SEQ ID NO:206, SEQ ID NO:208, SEQ ID NO:364, SEQ ID NO:366, SEQ ID NO:368, SEQ ID NO:370, SEQ ID NO:77, SEQ ID NO:372, SEQ ID NO:374, SEQ ID NO:79, SEQ ID NO:376, SEQ ID NO:378, SEQ ID NO:380, SEQ ID

NO:382, SEQ ID NO:384, SEQ ID NO:386, SEQ ID NO:388, SEQ ID NO:390 and SEQ ID NO:392, respectively. The amino acid sequences of the scFvs called SC05-140, SC05-157, SC05-159, SC05-166, SC05-179, SC05-187, SC06-016, SC06-043, SC06-049, SC05-050, SC06-071, SC06-077, SC06-078, SC06-079, SC06-086, SC06-087, SC06-089, SC06-092, SC06-191, SC06-195, SC06-198, SC06-241, SC06-242, SC06-246, SC06-252, SC06-388, SC06-389, SC06-396, SC06-402, SC06-409, SC06-415, SC06-421, SC06-429, and SC06-432 are shown in SEQ ID NO:351, SEQ ID NO:353, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:355, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:357, SEQ ID NO:74, SEQ ID NO:359, SEQ ID NO:76, SEQ ID NO:361, SEQ ID NO:363, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:365, SEQ ID NO:367, SEQ ID NO:369, SEQ ID NO:371, SEQ ID NO:78, SEQ ID NO:373, SEQ ID NO:375, SEQ ID NO:80, SEQ ID NO:377, SEQ ID NO:379, SEQ ID NO:381, SEQ ID NO:383, SEQ ID NO:385, SEQ ID NO:387, SEQ ID NO:389, SEQ ID NO:391 and SEQ ID NO:393, respectively. The VH and VL gene identity (see Tomlinson I M, Williams S C, Ignatovitch O, Corbett S J, Winter G. V-BASE Sequence Directory. Cambridge United Kingdom: MRC Centre for Protein Engineering (1997)) and CDR sequences of the scFvs specifically binding *enterococci* are depicted in Tables 10 and 11, respectively.

Example 6

Construction of Fully Human Immunoglobulin Molecules (Human Monoclonal Anti-Enterococcal Antibodies) from the Selected Anti-enterococcal Single Chain Fvs

Heavy and light chain variable regions of the scFv called SC05-140, SC05-157, SC05-159, SC05-166, SC05-179, SC05-187, SC06-016, SC06-043, SC06-049, SC05-050, SC06-071, SC06-077, SC06-078, SC06-079, SC06-086, SC06-087, SC06-089, SC06-092, SC06-191, SC06-195, SC06-198, SC06-241, SC06-242, SC06-246, SC06-252, SC06-388, SC06-389, SC06-396, SC06-402, SC06-409, SC06-415, SC06-421, SC06-429, and SC06-432 were cloned directly by restriction digest for expression in the IgG expression vectors pIg-C911-HCgamma1 (see SEQ ID NO:127), pIg-C909-Ckappa (see SEQ ID NO:128) and pIg-C910-Clambda (see SEQ ID NO:129). The heavy chain variable regions of the scFvs called SC05-140, SC05-157, SC05-159, SC05-166, SC05-179, SC05-187, SC06-016, SC06-043, SC06-049, SC05-050, SC06-071, SC06-077, SC06-078, SC06-079, SC06-086, SC06-087, SC06-089, SC06-092, SC06-191, SC06-195, SC06-198, SC06-241, SC06-242, SC06-246, SC06-252, SC06-388, SC06-389, SC06-396, SC06-402, SC06-409, SC06-415, SC06-421, SC06-429, and SC06-432 were cloned into the vector pIg-C911-HCgamma1 by restriction digest using the enzymes SfiI and XhoI. The light chain variable region of the scFv called SC06-016, SC06-050, SC06-077, SC06-086, SC06-191, SC06-241, SC06-396, and SC06-429 were cloned into the vector pIg-C909-Ckappa by restriction digest using the enzymes Sall, XhoI and Noll. The light chain variable region of the scFv called SC05-140, SC05-157, SC05-159, SC05-166, SC05-179, SC05-187, SC06-043, SC06-049, SC06-071, SC06-078, SC06-079, SC06-087, SC06-089, SC06-092, SC06-195, SC06-198, SC06-242, SC06-246, SC06-252, SC06-388, SC06-389, SC06-402, SC06-409, SC06-415, SC06-421, and SC06-432 were cloned into the vector pIg-C910-Clambda by restriction digest using the enzymes Sall, XhoI and Noll. Thereafter the nucleotide sequences were verified according to standard techniques.

The resulting expression pgG105-140C911, pgG105-157C911, pgG105-159C911, pgG105-166C911, pgG105-179C911, pgG105-187C911, pgG106-016C911, pgG106-043C911, pgG106-049C911, pgG106-050C911, pgG106-071C911, pgG106-077C911, pgG106-078C911, pgG106-079C911, pgG106-086C911, pgG106-087C911, pgG106-089C911, pgG106-092C911, pgG106-191C911, pgG106-195C911, pgG106-198C911, pgG106-0241C911, pgG106-242C911, pgG106-246C911, pgG106-252C911, pgG106-388C911, pgG106-389C911, pgG106-396C911, pgG106-402C911, pgG106-409C911, pgG106-415C911, pgG106-421C911, pgG106-429C911, and pgG106-432C911 encoding anti-*enterococci* human IgG1 heavy chains and pgG105-140C910, pgG105-157C910, pgG105-159C910, pgG105-166C910, pgG105-179C910, pgG105-187C910, pgG106-016C909, pgG106-043C910, pgG106-049C910, pgG106-050C909, pgG106-071C910, pgG106-077C909, pgG106-078C910, pgG106-079C910, pgG106-086C909, pgG106-087C910, pgG106-089C910, pgG106-092C910, pgG106-191C909, pgG106-195C910, pgG106-198C910, pgG106-0241C909, pgG106-242C910, pgG106-246C910, pgG106-252C910, pgG106-388C910, pgG106-389C910, pgG106-396C909, pgG106-402C910, pgG106-409C910, pgG106-415C910, pgG106-421C910, pgG106-429C909, and pgG106-432C910 encoding the anti-*enterococci* human Ig light chains were transiently expressed in combination in 293T cells and supernatants containing human IgG1 antibodies were obtained. The nucleotide sequences of the heavy chains of the antibodies called CR5140, CR5157, CR5159, CR5166, CR5179, CR5187, CR6016, CR6043, CR6049, CR6050, CR6071, CR6077, CR6078, CR6079, CR6086, CR6087, CR6089, CR6092, CR6191, CR6195, CR6198, CR6241, CR6242, CR6246, CR6252, CR6388, CR6389, CR6396, CR6402, CR6409, CR6415, CR6421, CR6429, and CR6432 are shown in SEQ ID NO:394, SEQ ID NO:396, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:398, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:400, SEQ ID NO:93, SEQ ID NO:402, SEQ ID NO:95, SEQ ID NO:404, SEQ ID NO:406, SEQ ID NO:210, SEQ ID NO:212, SEQ ID NO:408, SEQ ID NO:410, SEQ ID NO:412, SEQ ID NO:414, SEQ ID NO:97, SEQ ID NO:416, SEQ ID NO:418, SEQ ID NO:99, SEQ ID NO:420, SEQ ID NO:422, SEQ ID NO:424, SEQ ID NO:426, SEQ ID NO:428, SEQ ID NO:430, SEQ ID NO:432, SEQ ID NO:434, and SEQ ID NO:436, respectively. The amino acid sequences of the heavy chains of the antibodies called CR5140, CR5157, CR5159, CR5166, CR5179, CR5187, CR6016, CR6043, CR6049, CR6050, CR6071, CR6077, CR6078, CR6079, CR6086, CR6087, CR6089, CR6092, CR6191, CR6195, CR6198, CR6241, CR6242, CR6246, CR6252, CR6388, CR6389, CR6396, CR6402, CR6409, CR6415, CR6421, CR6429, and CR6432, are shown in SEQ ID NO:395, SEQ ID NO:397, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:399, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:401, SEQ ID NO:94, SEQ ID NO:403, SEQ ID NO:96, SEQ ID NO:405, SEQ ID NO:407, SEQ ID NO:211, SEQ ID NO:213, SEQ ID NO:409, SEQ ID NO:411, SEQ ID NO:413, SEQ ID NO:415, SEQ ID NO:98, SEQ ID NO:417, SEQ ID NO:419, SEQ ID NO:100, SEQ ID NO:421, SEQ ID NO:423, SEQ ID NO:425, SEQ ID NO:427, SEQ ID NO:429, SEQ ID NO:431, SEQ ID NO:433, SEQ ID NO:435, and SEQ ID NO:437, respectively.

The nucleotide sequences of the light chain of antibodies CR5140, CR5157, CR5159, CR5166, CR5179, CR5187, CR6016, CR6043, CR6049, CR6050, CR6071, CR6077, CR6078, CR6079, CR6086, CR6087, CR6089, CR6092,

CR6191, CR6195, CR6198, CR6241, CR6242, CR6246, CR6252, CR6388, CR6389, CR6396, CR6402, CR6409, CR6415, CR6421, CR6429, and CR6432 are shown in SEQ ID NO:438, SEQ ID NO:440, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:442, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:444, SEQ ID NO:113, SEQ ID NO:446, SEQ ID NO:115, SEQ ID NO:448, SEQ ID NO:450, SEQ ID NO:214, SEQ ID NO:216, SEQ ID NO:452, SEQ ID NO:454, SEQ ID NO:456, SEQ ID NO:458, SEQ ID NO:117, SEQ ID NO:460, SEQ ID NO:462, SEQ ID NO:119, SEQ ID NO:464, SEQ ID NO:466, SEQ ID NO:468, SEQ ID NO:470, SEQ ID NO:472, SEQ ID NO:474, SEQ ID NO:476, SEQ ID NO:478, and SEQ ID NO:480, respectively. The amino acid sequences of the light chain of antibodies CR5140, CR5157, CR5159, CR5166, CR5179, CR5187, CR6016, CR6043, CR6049, CR6050, CR6071, CR6077, CR6078, CR6079, CR6086, CR6087, CR6089, CR6092, CR6191, CR6195, CR6198, CR6241, CR6242, CR6246, CR6252, CR6388, CR6389, CR6396, CR6402, CR6409, CR6415, CR6421, CR6429, and CR6432 are shown in SEQ ID NO:439, SEQ ID NO:441, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:443, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:445, SEQ ID NO:114, SEQ ID NO:447, SEQ ID NO:116, SEQ ID NO:449, SEQ ID NO:451, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:453, SEQ ID NO:455, SEQ ID NO:457, SEQ ID NO:459, SEQ ID NO:118, SEQ ID NO:461, SEQ ID NO:463, SEQ ID NO:120, SEQ ID NO:465, SEQ ID NO:467, SEQ ID NO:469, SEQ ID NO:471, SEQ ID NO:473, SEQ ID NO:475, SEQ ID NO:477, SEQ ID NO:479, and SEQ ID NO:481, respectively. One can determine the variable regions of the heavy and light chains of the above antibodies by following Kabat et al. (1991) as described in Sequences of Proteins of Immunological Interest. Table 12 provides the variable regions of the antibodies.

The human anti-enterococcal IgG1 antibodies were validated for their ability to bind to *enterococci* by ELISA essentially as described for scFvs above; IgG1 were assayed at a concentration of 5 µg/ml except for the following IgG1s: CR6191 was assayed at 1.6 µg/ml, CR6195 at 3.1 µg/ml, CR6198 at 4.1 µg/ml, CR6241 at 2.7 µg/ml, CR6246 at 2.6 µg/ml and CR6252 at 3.0 µg/ml. The negative control was an anti-West Nile virus antibody (CR4374). In addition, the human anti-enterococcal IgG1 antibodies were tested for their ability to bind to different clinical isolates of *Enterococcus faecalis* and *Enterococcus faecium* (see Table 13). An antibody was considered to bind to an isolate, when the value within an individual experiment was at least three-fold compared to the value of the negative control within that individual experiment. The value of the negative control in Table 13 is an average of 6 experiments. All antibodies except CR5157, CR5179, CR6016, CR6043, CR6050, CR6246, CR6388, CR6409 and the negative control antibody specifically bound to *E. faecalis* strain 12030 and all IgG1s with the exception of CR5157, CR6016, CR6043, CR6050, CR6241, CR6242, CR6246, CR6388 and CR6409 bound to more than one clinical isolate. Antibodies CR5187, CR6049, CR6396, CR6402 and CR6421 bound to all *E. faecalis* strains tested and the two *E. faecium* strains tested. Alternatively, batches of greater than 1 mg of each antibody were produced and purified using standard procedures.

In Vitro Opsonic Phagocytic Activity of Enterococcal Specific IgGs Measured by Opsonophagocytic Killing Assay

An opsonophagocytic assay was conducted to quantify the killing activity of anti-*enterococci* human IgG1 against the enterococcal clinical isolate 12030. Freshly drawn human blood (10 to 30 ml) was mixed with an equal volume of dextran-heparin buffer (4.5 g of dextran, Sigma Chemical, St. Louis, Mo.; 28.4 mg of heparin sodium in 500 ml of distilled water), and the mixture was incubated at 37° C. for 1 hour. The upper layer containing the leukocytes was collected by centrifugation, and hypotonic lysis of the remaining erythrocytes was accomplished by suspension of the cell pellet in 1% (w/v) NH₄Cl. The leukocyte population was subsequently washed in RPMI with 15% fetal bovine serum. Trypan blue staining and counting in a hemocytometer were used to determine the concentration of live leukocytes, and the final leukocyte concentration was adjusted to 2×10⁷ cells/ml. The phagocytosis assay was performed in duplicate with or without 100 µl of leukocyte suspension added to 100 µl of bacteria (concentration adjusted spectrophotometrically to 2×10⁷ per ml and confirmed by viable counts), 100 µl of anti-*enterococci* human IgG1 diluted in RPMI, and 100 µl of baby rabbit complement. The reaction mixture was incubated on a rotor rack at 37° C. for 90 minutes; samples were taken at time 0 and after 90 minutes, diluted in 1% Proteose Peptone (Difco Laboratories, Detroit, Mich.), and plated onto tryptic soy agar plates. The killing activity (%) of the antibodies was calculated as the mean number of CFU surviving in the sample containing leukocytes subtracted from the mean number of CFU surviving in the sample without leukocytes, divided by the latter, and amplified by 100. Four concentrations of the anti-*enterococci* human IgG1 were tested (2500, 250, 25, 2.5 ng/ml) in two independent experiments. Ordinal regression analysis applying the probit model was used to calculate the concentrations required for 50% killing of bacteria in the assay (see Table 14).

Example 8

In Vivo Activity of Enterococcal Specific IgGs in a Murine Sepsis Model

A murine sepsis model of *enterococcus* (see Huihagel et al. 2004) was used to quantify activity of anti-*enterococci* human IgG1 in clearing the enterococcal clinical isolate 12030 from the bloodstream. The purified IgG1 molecules CR5159, CR5187, CR6016, CR6043, CR6049, CR6071, CR6089, and CR6241 demonstrated to have in vitro killing activity against *Enterococcus* and one negative control IgG1 having no killing activity against *Enterococcus* were prepared as described above and were injected i.p. (0.5-1 ml in PBS) into groups of eight BALB/c mice at a dose of 15 mg/kg, with the exception of CR6016 and CR6241 which were injected at a dose of 7.5 mg/kg. In addition, one group of mice was injected with PBS. After 24 hours animals were inoculated i.v. with 6×10⁸ CFU of *Enterococcus* strain 12030. Four hours after the bacterial challenge mice received a second i.p. injection of CR5159, CR5187, CR6016, CR6043, CR6049, CR6071, CR6089, and CR6241 at the same dose. Three days after systemic infection animals were euthanised and ~0.5 ml of blood collected by cardiac puncture. Blood samples were cultured quantitatively on enterococcal selective agar medium; 100 µl of blood diluted in 900 µl of THB was spread out onto plates in duplicate. After overnight incubation the number of CFU was read off the plate and multiplied by 10 to give the CFU/ml of blood.

This value is directly related to the amount of circulating bacteria at the time of sacrifice.

The primary endpoint in this model is CFU of *Enterococcus* in the blood 3 days after inoculation. As shown in FIG. 1 all of the animals that received PBS or control IgG1 had $>10^2$ CFU/ml of *Enterococcus* in their blood after 3 days and the median was $\sim 10^3$ CFU/ml. In contrast, all of the groups that received anti-enterococcal antibodies contained animals with $<10^2$ CFU/ml of *Enterococcus* in the blood. In addition, in all but one case, CR5187, the median was one log below that of the controls. One antibody, CR6089, had a median below the level of sensitivity in the assay (10 CFU/ml) and in 6 out of 8 animals there was no detectable bacteria in the blood. CR6016 and CR6241 that were used at a lower dose still had medians close to 10 CFU/ml of blood indicating that they are of high potency. Non-parametric analysis of variance (Kruskal-Wallis) established that the differences were highly significant ($p < 0.001$). Pairwise comparisons were performed between the test IgG1 and negative control IgG1 using the Mann-Whitney test with the Bonferroni correction. Antibodies CR5159, CR5187, CR6043, CR6049, CR6089, and CR6241 were all significantly different ($p < 0.05$) to the control antibody, while the median difference of the antibodies CR6043 and CR6071 did not reach significance when compared to the control antibody.

Example 9

IgG1 Competition Assay

To establish whether antibodies in the panel competed for binding to the same target a competition ELISA was developed. The enterococcal strain 12030 was streaked onto a blood agar plate and incubated overnight at 37° C. Colonies were scraped from the plate using 5 ml of a 50 mM carbonate buffer (8 volumes of 0.2 M Na₂CO₃, 17 volumes of 0.2 M NaHCO₃ and 75 volumes of distilled water) and centrifuged for 3 minutes at 4000 rpm. The pellet obtained was resuspended in 500 µl of carbonate buffer, centrifuged again and the pellet was resuspended in 500 µl carbonate buffer. Cell density was determined by measuring OD₆₀₀ of a dilution series of the bacteria.

The *enterococcus* strain was diluted to a density of 5×10^9 cells/ml and 100 µl (5×10^8 cells) per well was coated overnight at 4° C. on Nunc-Immuno Maxisorp F96 plates. After incubation, the wells were washed three times with PBS and blocked for 1 hour at room temperature with 300 µl 2% (v/v) ELK in PBS per well. In separate tubes 25 µl of each scFv-phage maxiprep (produced as above) diluted to subsaturating levels (as determined by ELISA above) was mixed with 25 µl blocking buffer (4% (v/v) ELK in PBS) and 50 µl of IgG1 supernatant diluted to 10 µg/ml in PBS. The mixture was incubated for 20 minutes on ice. After removing the blocking solution from the wells, 100 µl of the mixture was added to each well and incubated for 1 hour at room temperature. Next, the wells were washed three times with PBS/0.01% (v/v) Tween® and once with PBS. After washing, 100 µl of anti-M13 HRP (1:5000 in 2% (v/v) ELK in PBS) was added per well and incubated for 60 minutes at room temperature. The wells were washed again and staining was visualized by adding 100 µl OPD-solution to each well. The visualization reaction was stopped after 5-10 minutes by adding 50 µl 1M H₂SO₄ to each well and the OD was measured at 492 nm. The experiment was repeated twice with the entire panel of antibodies and the control IgG1 CR4374. The results showed that the antibodies could be divided into several distinct groups. Group A consisted of CR6089 and CR6092; Group B consisted of CR5157, CR5187, CR6043, CR6049, CR6388,

CR6389, CR6396, CR6402, CR6409, CR6421, and CR6429; and Group C consisted of CR5159, CR5166, CR6050, CR6077, CR6078, CR6086, and CR6191 and the rest of the antibodies CR5140, CR5179, CR6016, CR6071, CR6079, CR6087, CR6195, CR6198, CR6241, CR6242, CR6246, CR6252, CR6415, and CR6432 did not compete with any other antibody for binding.

Example 10

In Vitro Opsonic Phagocytic Activity of Anti-enterococcal IgG1 Molecules Against Different *E. faecalis*, *E. faecium* and *S. aureus* Strains Measured by Opsonophagocytic Killing Assay

To determine the breadth of killing activity of the anti-enterococcal monoclonal antibody panel, purified batches of IgG1 made as described above were assayed for killing activity in the opsonophagocytic killing assay described above. An additional *E. faecalis* strain, Type 2; two different *E. faecium* clinical isolates, 740220 and 838970; and the *S. aureus* clinical isolate 502 were tested. Eighteen antibodies were chosen from the original panel of 34 based on non-competing binding capacity and potency in the opsonophagocytic killing assay. As shown in Table 15, the chosen panel showed killing activity against the *E. faecium* strains at two concentrations, 2.5 and 0.025 µg/ml, although the activity of CR5140, CR6016 and CR6078 was lower than 20% against strain 838970 at the highest concentration. All but one antibody had measurable activity against *E. faecalis* strain Type 2, although 11 out of 18 antibodies had less than 25% killing activity at the highest concentration tested. Surprisingly, all antibodies of the panel had killing activity against the *S. aureus* strain 502, indicating that the antibodies recognize broadly cross-reactive targets. We tested whether any of the antibodies bind to lipoteichoic acid (LTA) of *S. aureus*, and none of these antibodies appeared to do so. Three of the antibodies (CR6252, CR6415 and CR6421) were tested for opsonic phagocytic killing activity against another *Staphylococcus aureus* strain (Newman), and against a *S. epidermidis* strain (RP62A), and all three antibodies tested showed killing activity against these different *Staphylococcus* species and strains.

TABLE 1

Human lambda chain variable region primers (sense).		
Primer name	Primer nucleotide sequence	SEQ ID NO
HuVL1A-Back	5' - CAGTCTGTGCTGACT CAGCCACC - 3'	SEQ ID NO: 130
HuVL1B-Back	5' - CAGTCTGTGYTGACG CAGCCGCC - 3'	SEQ ID NO: 131
HuVL1C-Back	5' - CAGTCTGTCGTGACG CAGCCGCC - 3'	SEQ ID NO: 132
HuVL2B-Back	5' - CAGTCTGCCCTGACT CAGCC - 3'	SEQ ID NO: 133
HuVL3A-Back	5' - TCCTATGWGCTGACT CAGCCACC - 3'	SEQ ID NO: 134
HuVL3B-Back	5' - TCTTCTGAGCTGACT CAGGACCC - 3'	SEQ ID NO: 135
HuVL4B-Back	5' - CAGCYTGTGCTGACT CAATC - 3'	SEQ ID NO: 136

41

TABLE 1-continued

Human lambda chain variable region primers (sense).		
Primer name	Primer nucleotide sequence	SEQ ID NO
HuVL5-Back	5'-CAGGCTGTGCTGACT CAGCCGTC-3'	SEQ ID NO: 137
HuVL6-Back	5'-AATTTTATGCTGACT CAGCCCA-3'	SEQ ID NO: 138
HuVL7/8-Back	5'-CAGRCTGTGGTGACY CAGGAGCC-3'	SEQ ID NO: 139
HuVL9-Back	5'-CWGCCTGTGCTGACT CAGCCMC-3'	SEQ ID NO: 140
HuVL10-Back	5'-CAGGCAGGGCTGACT CAG-3'	SEQ ID NO: 141

TABLE 2

Human kappa chain variable region primers (sense).		
Primer name	Primer nucleotide sequence	SEQ ID NO
HuVK1B-Back	5'-GACATCCAGWTGACCC AGTCTCC-3'	SEQ ID NO: 142
HuVK2-Back	5'-GATGTTGTGATGACT CAGTCTCC-3'	SEQ ID NO: 143
HuVK2B2	5'-GATATTGTGATGACC CAGACTCC-3'	SEQ ID NO: 144
HuVK3B-Back	5'-GAAATTGTGWTGACR CAGTCTCC-3'	SEQ ID NO: 145
HuVK5-Back	5'-GAAACGACACTCAGC CAGTCTCC-3'	SEQ ID NO: 146
HuVK6-Back	5'-GAAATTGTGCTGACTC AGTCTCC-3'	SEQ ID NO: 147

TABLE 3

Human kappa chain variable region primers extended with SalI restriction sites (sense), human kappa chain J-region primers extended with NotI restriction sites (anti-sense), human lambda chain variable region primers extended with SalI restriction sites (sense) and human lambda chain J-region primers extended with NotI restriction sites (anti-sense).		
Primer name	Primer nucleotide sequence	SEQ ID NO
HuVK1B-Back-SAL	5'-TGAGCACACAGGTCG ACGGACATCCAGWTGACC CAGTCTCC-3'	SEQ ID NO: 148
HuVK2-Back-SAL	5'-TGAGCACACAGGTCG ACGGATGTTGTGATGACT CAGTCTCC-3'	SEQ ID NO: 149
HuVK2B2-SAL	5'-TGAGCACACAGGTCG ACGGATATTGTGATGACC CAGACTCC-3'	SEQ ID NO: 150
HuVK3B-Back-SAL	5'-TGAGCACACAGGTCG ACGGAAATTGTGWTGACR	SEQ ID NO: 151

42

TABLE 3-continued

Human kappa chain variable region primers extended with SalI restriction sites (sense), human kappa chain J-region primers extended with NotI restriction sites (anti-sense), human lambda chain variable region primers extended with SalI restriction sites (sense) and human lambda chain J-region primers extended with NotI restriction sites (anti-sense).		
Primer name	Primer nucleotide sequence	SEQ ID NO
HuVK5-Back-SAL	5'-TGAGCACACAGGTCGACG GAAACGACACTCAGCAGTCT CC-3'	SEQ ID NO: 152
HuVK6-Back-SAL	5'-TGAGCACACAGGTCG ACGGAAATTGTGCTGACT CAGTCTCC-3'	SEQ ID NO: 153
HuJK1-FOR-NOT	5'-GAGTCATTCTCGACTTGC GGCCGCACGTTTGATTTCCAC CTTGGTCCC-3'	SEQ ID NO: 154
HuJK2-FOR-NOT	5'-GAGTCATTCTCGACT TGCGCCGCACGTTTGAT CTCCAGCTTGGTCCC-3'	SEQ ID NO: 155
HuJK3-FOR-NOT	5'-GAGTCATTCTCGACTTGC GGCCGCACGTTTGATATCCAC TTTGGTCCC-3'	SEQ ID NO: 156
HuJK4-FOR-NOT	5'-GAGTCATTCTCGACT TGCGCCGCACGTTTGAT CTCCACCTTGGTCCC-3'	SEQ ID NO: 157
HuJK5-FOR-NOT	5'-GAGTCATTCTCGACTTGC GGCCGCACGTTTAATCTCCAG TCGTGTCCC-3'	SEQ ID NO: 158
HuVL1A-Back-SAL	5'-TGAGCACACAGGTCGACG CAGTCTGTGCTGACTCAGCCA CC-3'	SEQ ID NO: 159
HuVL1B-Back-SAL	5'-TGAGCACACAGGTCGACG CAGTCTGTGYTGACGCAGCCG CC-3'	SEQ ID NO: 160
HuVL1C-Back-SAL	5'-TGAGCACACAGGTCGACG CAGTCTGTCGTGACGCAGCCG CC-3'	SEQ ID NO: 161
HuVL2B-Back-SAL	5'-TGAGCACACAGGTCGACG CAGTCTGCCCTGACTCAGCC-3'	SEQ ID NO: 162
HuVL3A-Back-SAL	5'-TGAGCACACAGGTCGACG TCCTATGWGCTGACTCAGCCA CC-3'	SEQ ID NO: 163
HuVL3B-Back-SAL	5'-TGAGCACACAGGTCGACG TCTTCTGAGCTGACTCAGGAC CC-3'	SEQ ID NO: 164
HuVL4B-Back-SAL	5'-TGAGCACACAGGTCGACG CAGCYTGTGCTGACTCAATC-3'	SEQ ID NO: 165
HuVL5-Back-SAL	5'-TGAGCACACAGGTCGACG CAGGCTGTGCTGACTCAGCCG TC-3'	SEQ ID NO: 166
HuVL6-Back-SAL	5'-TGAGCACACAGGTCGACG AATTTTATGCTGACTCAGCCC CA-3'	SEQ ID NO: 167
HuVL7/8-Back-SAL	5'-TGAGCACACAGGTCGACG CAGRCTGTGGTGACYCAGGAG CC-3'	SEQ ID NO: 168

TABLE 3-continued

Human kappa chain variable region primers extended with Sall restriction sites (sense), human kappa chain J-region primers extended with NotI restriction sites (anti-sense), human lambda chain variable region primers extended with Sall restriction sites (sense) and human lambda chain J-region primers extended with NotI restriction sites (anti-sense).

Primer name	Primer nucleotide sequence	SEQ ID NO
HuVL9-Back-SAL	5'-TGAGCACACAGGTCGACG CWGCCTGTGCTGACTCAGCCM CC-3'	SEQ ID NO: 169
HuVL10-Back-SAL	5'-TGAGCACACAGGTCGACG CAGGCAGGGCTGACTCAG-3'	SEQ ID NO: 170
HuJL1-FOR-NOT	5'-GAGTCATTCTCGACTTGC GGCCGCACCTAGGACGGTGAC CTTGGTCCC-3'	SEQ ID NO: 171
HuJL2/3-FOR-NOT	5'-GAGTCATTCTCGACTTGC GGCCGCACCTAGGACGGTCAG CTTGGTCCC-3'	SEQ ID NO: 172
HuJL7-FOR-NOT	5'-GAGTCATTCTCGACTTGC GGCCGCACCGAGGACGGTCAG CTGGGTGCC-3'	SEQ ID NO: 173

TABLE 4

Percentage of the different light chain products in the final mixture, based on concentrations determined by agarose gel analysis.			
Sense primer	Antisense primer	Product	Percentage
HuVL1A-Back-SAL +	HuJL1-FOR-NOT	L1J1	4.20%
HuVL1B-Back-SAL +	HuJL2/3-FOR-NOT	L1J2	8.40%
HuVL1C-Back-SAL	HuJL7-FOR-NOT	L1J3	1.40%
HuVL2B-Back-SAL	HuJL1-FOR-NOT	L2J1	3.00%
	HuJL2/3-FOR-NOT	L2J2	6.00%
	HuJL7-FOR-NOT	L2J3	1.00%
HuVL3A-Back-SAL	HuJL1-FOR-NOT	L3J1	3.00%
	HuJL2/3-FOR-NOT	L3J2	6.00%
	HuJL7-FOR-NOT	L3J3	1.00%
HuVL3B-Back-SAL	HuJL1-FOR-NOT	L4J1	0.30%
	HuJL2/3-FOR-NOT	L4J2	0.60%
	HuJL7-FOR-NOT	L4J3	0.10%
HuVL4B-Back-SAL	HuJL1-FOR-NOT	L5J1	0.30%
	HuJL2/3-FOR-NOT	L5J2	0.60%
	HuJL7-FOR-NOT	L5J3	0.10%
HuVL5-Back-SAL	HuJL1-FOR-NOT	L6J1	0.30%
	HuJL2/3-FOR-NOT	L6J2	0.60%
	HuJL7-FOR-NOT	L6J3	0.10%
HuVL6-Back-SAL	HuJL1-FOR-NOT	L7J1	0.30%
	HuJL2/3-FOR-NOT	L7J2	0.60%
	HuJL7-FOR-NOT	L7J3	0.10%
HuVL7/8-Back-SAL	HuJL1-FOR-NOT	L8J1	0.30%
	HuJL2/3-FOR-NOT	L8J2	0.60%
	HuJL7-FOR-NOT	L8J3	0.10%
HuVL9-Back-SAL +	HuJL1-FOR-NOT	L9J1	0.30%
HuVL10-Back-SAL	HuJL2/3-FOR-NOT	L9J2	0.60%
	HuJL7-FOR-NOT	L9J3	0.10%
HuVK1B-Back-SAL	HuJK1-FOR-NOT	K1J1	7.50%
	HuJK2-FOR-NOT	K1J2	7.50%
	HuJK3-FOR-NOT	K1J3	3.00%
	HuJK4-FOR-NOT	K1J4	7.50%
	HuJK5-FOR-NOT	K1J5	4.50%
HuVK2-Back-SAL	HuJK1-FOR-NOT	K2J1	1.00%
	HuJK2-FOR-NOT	K2J2	1.00%
	HuJK3-FOR-NOT	K2J3	0.40%
	HuJK4-FOR-NOT	K2J4	1.00%
	HuJK5-FOR-NOT	K2J5	0.60%

TABLE 4-continued

Percentage of the different light chain products in the final mixture, based on concentrations determined by agarose gel analysis.				
Sense primer	Antisense primer	Product	Percentage	
5	HuVK2B2-SAL	HuJK1-FOR-NOT	K3J1	0.25%
		HuJK2-FOR-NOT	K3J2	0.25%
		HuJK3-FOR-NOT	K3J3	0.10%
		HuJK4-FOR-NOT	K3J4	0.25%
		HuJK5-FOR-NOT	K3J5	0.15%
10	HuVK3B-Back-SAL	HuJK1-FOR-NOT	K4J1	4.75%
		HuJK2-FOR-NOT	K4J2	4.75%
		HuJK3-FOR-NOT	K4J3	1.90%
		HuJK4-FOR-NOT	K4J4	4.75%
		HuJK5-FOR-NOT	K4J5	2.85%
15	HuVK5-Back-SAL	HuJK1-FOR-NOT	K5J1	0.25%
		HuJK2-FOR-NOT	K5J2	0.25%
		HuJK3-FOR-NOT	K5J3	0.10%
		HuJK4-FOR-NOT	K5J4	0.25%
		HuJK5-FOR-NOT	K5J5	0.15%
20	HuVK6-Back-SAL	HuJK1-FOR-NOT	K6J1	1.25%
		HuJK2-FOR-NOT	K6J2	1.25%
		HuJK3-FOR-NOT	K6J3	0.50%
		HuJK4-FOR-NOT	K6J4	1.25%
		HuJK5-FOR-NOT	K6J5	0.75%

TABLE 5

Human IgG heavy chain variable region primers (sense).			
Primer name	Primer nucleotide sequence	SEQ ID NO	
30	HuVH1B/7A-Back	5'-CAGRTGCAGCTGGTG CARTCTGG-3'	SEQ ID NO: 174
35	HuVH1C-Back	5'-SAGGTCCAGCTGGTR CAGTCTGG-3'	SEQ ID NO: 175
	HuVH2B-Back	5'-CAGRTCACCTGAAG GAGTCTGG-3'	SEQ ID NO: 176
40	HuVH3A-Back	5'-GAGGTGCAGCTGGTG GAG-3'	SEQ ID NO: 177
	HuVH3C-Back	5'-GAGGTGCAGCTGGTG GAGWCYGG-3'	SEQ ID NO: 178
45	HuVH4B-Back	5'-CAGGTGCAGCTACAG CAGTGGGG-3'	SEQ ID NO: 179
	HuVH4C-Back	5'-CAGSTGCAGCTGCAG GAGTCSGG-3'	SEQ ID NO: 180
50	HuVH6A-Back	5'-CAGGTACAGCTGCAG CAGTCAGG-3'	SEQ ID NO: 181

TABLE 6

Human IgG heavy chain variable region primers extended with SfiI/NcoI restriction sites (sense) and human IgG heavy chain J-region primers extended with XhoI/BstEII restriction sites (anti-sense).			
Primer name	Primer nucleotide sequence	SEQ ID NO	
55	HuVH1B/7A-Back-Sfi	5'-GTCCTCGCAACTGCG GCCAGCCGGCCATGGCC CAGRTGCAGCTGGTG TCTGG-3'	SEQ ID NO: 182
60			
65			

45

TABLE 6-continued

Human IgG heavy chain variable region primers extended with SfiI/NcoI restriction sites (sense) and human IgG heavy chain J-region primers extended with XhoI/BstEII restriction sites (anti-sense).		
Primer name	Primer nucleotide sequence	SEQ ID NO
HuVH1C-Back-Sfi	5'-GTCCTCGCAACTGCG GCCAGCCGGCCATGGCC SAGGTCCAGCTGGTRCAG TCTGG-3'	SEQ ID NO: 183
HuVH2B-Back-Sfi	5'-GTCCTCGCAACTGCG GCCAGCCGGCCATGGCC CAGRTCACCTGAAGGAG TCTGG-3'	SEQ ID NO: 184
HuVH3A-Back-Sfi	5'-GTCCTCGCAACTGCGGCC CAGCCGGCCATGGCCGAGGTG CAGCTGGTGGAG-3'	SEQ ID NO: 185
HuVH3C-Back-Sfi	5'-GTCCTCGCAACTGCG GCCAGCCGGCCATGGCC GAGGTGCAGCTGGTGGAG WCYGG-3'	SEQ ID NO: 186
HuVH4B-Back-Sfi	5'-GTCCTCGCAACTGCG GCCAGCCGGCCATGGCC CAGGTGCAGCTACAGCAG TGGGG-3'	SEQ ID NO: 187
HuVH4C-Back-Sfi	5'-GTCCTCGCAACTGCGGCC CAGCCGGCCATGGCCGAGSTG CAGCTGCAGGAGTCSGG-3'	SEQ ID NO: 188
HuVH6A-Back-Sfi	5'-GTCCTCGCAACTGCG GCCAGCCGGCCATGGCC CAGGTACAGCTGCAGCAG TCAGG-3'	SEQ ID NO: 189
HuJH1/2-FOR-XhoIB	5'-GAGTCATTCTCGACTCGA GACRGTGACCGGGTGCC-3'	SEQ ID NO: 190
HuJH3-FOR-Xho	5'-GAGTCATTCTCGACT CGAGACGGTGACCATTGT CCC-3'	SEQ ID NO: 191
HuJH4/5-FOR-Xho	5'-GAGTCATTCTCGACT CGAGACGGTGACCAGGGT TCC-3'	SEQ ID NO: 192
HuJH6-FOR-Xho	5'-GAGTCATTCTCGACTCGA GACGGTGACCGTGGTCCC-3'	SEQ ID NO: 193

TABLE 7

Percentage of the different heavy chain products in the final mixture.			
Sense primer	Antisense primer	Product	Percentage
HuVH1B/7A-Back-Sfi + HuVH1C-Back-Sfi	HuJH1/2-FOR-XhoIB	H1J1	2.5%
	HuJH3-FOR-Xho	H1J2	2.5%
	HuJH4/5-FOR-Xho	H1J3	15.0%
	HuJH6-FOR-Xho	H1J4	5.0%
HuVH2B-Back-Sfi	HuJH1/2-FOR-XhoIB	H2J1	0.2%
	HuJH3-FOR-Xho	H2J2	0.2%
	HuJH4/5-FOR-Xho	H2J3	1.2%
	HuJH6-FOR-Xho	H2J4	0.4%
HuVH3A-Back-Sfi	HuJH1/2-FOR-XhoIB	H3J1	2.5%
	HuJH3-FOR-Xho	H3J2	2.5%
	HuJH4/5-FOR-Xho	H3J3	15.0%
	HuJH6-FOR-Xho	H3J4	5.0%
HuVH3C-Back-Sfi	HuJH1/2-FOR-XhoIB	H4J1	2.5%
	HuJH3-FOR-Xho	H4J2	2.5%

46

TABLE 7-continued

Percentage of the different heavy chain products in the final mixture.			
Sense primer	Antisense primer	Product	Percentage
5 HuVH4B-Back-Sfi	HuJH4/5-FOR-Xho	H4J3	15.0%
	HuJH6-FOR-Xho	H4J4	5.0%
	HuJH1/2-FOR-XhoIB	H5J1	0.2%
	HuJH3-FOR-Xho	H5J2	0.2%
10 HuVH4C-Back-Sfi	HuJH4/5-FOR-Xho	H5J3	1.2%
	HuJH6-FOR-Xho	H5J4	0.4%
	HuJH1/2-FOR-XhoIB	H6J1	2.0%
	HuJH3-FOR-Xho	H6J2	2.0%
15 HuVH6A-Back-Sfi	HuJH4/5-FOR-Xho	H6J3	12.0%
	HuJH6-FOR-Xho	H6J4	4.0%
	HuJH1/2-FOR-XhoIB	H7J1	0.1%
	HuJH3-FOR-Xho	H7J2	0.1%
20	HuJH4/5-FOR-Xho	H7J3	0.6%
	HuJH6-FOR-Xho	H7J4	0.2%

TABLE 8

Enterococcal strains used for selection and screening of anti-enterococcal single-chain (scFv) phage antibodies.

Strain	Source
<i>E. faecalis</i> 12030	Veterans Administration Hospital, Cleveland, Ohio
<i>E. faecalis</i> T2	Prototype Japanese strain
<i>E. faecalis</i> 6814	Brigham and Women's Hospital, Boston, Massachusetts
<i>E. faecalis</i> B8610A	Brigham and Women's Hospital, Boston, Massachusetts
<i>E. faecium</i> 740220	Brigham and Women's Hospital, Boston, Massachusetts
<i>E. faecium</i> B210860	Brigham and Women's Hospital, Boston, Massachusetts

TABLE 9

Enterococcal specific binding activity of single-chain (scFv) phage antibodies as measured by ELISA.

Name phage	<i>Enterococcus</i> strains (OD492 nm)		Control antigens (OD492 nm)		
	12030	T2	BSA	ELK	
antibody					
45	SC05-140	1.094	ND	0.226	0.152
	SC05-157	0.787	ND	0.058	0.106
	SC05-159	0.612	ND	0.060	0.089
	SC05-166	0.954	ND	0.104	0.099
	SC05-179	0.804	ND	0.045	0.047
	SC05-187	0.835	1.043	0.055	0.055
	SC06-016	0.842	ND	0.044	0.041
	SC06-043	0.705	ND	0.045	0.042
	SC06-049	0.241	ND	0.042	0.043
	SC06-050	0.410	ND	0.043	0.043
	SC06-071	0.703	0.746	0.043	0.042
	SC06-077	0.577	1.005	0.044	0.060
	SC06-078	0.596	1.040	0.073	0.044
	SC06-079	0.663	0.953	0.048	0.041
50	SC06-086	0.587	ND	0.062	0.053
	SC06-087	0.553	ND	0.044	0.060
	SC06-089	0.613	ND	0.042	0.063
	SC06-092	0.624	ND	0.047	0.050
	SC06-191	0.456	0.498	0.044	0.039
	SC06-195	0.661	0.789	0.046	0.043
	SC06-198	0.999	1.169	0.049	0.044
	SC06-241	1.107	0.122	0.052	0.045
	SC06-242	0.814	0.085	0.043	0.043
	SC06-246	0.588	0.636	0.042	0.040
	SC06-252	0.638	0.304	0.044	0.039
	SC06-388	1.006	1.301	ND	0.040
	SC06-389	1.337	1.743	ND	0.038
	SC06-396	0.689	1.166	ND	0.067

47

TABLE 9-continued

Enterococcal specific binding activity of single-chain (scFv) phage antibodies as measured by ELISA.				
Name phage antibody	<i>Enterococcus</i> strains (OD492 nm)		Control antigens (OD492 nm)	
	12030	T2	BSA	ELK
SC06-402	1.538	1.905	ND	0.126
SC06-409	0.876	1.339	0.055	0.051
SC06-415	0.889	1.565	0.044	0.049
SC06-421	3.150	3.270	0.607	0.133
SC06-429	1.101	2.453	0.068	0.043

5

10

48

TABLE 9-continued

Enterococcal specific binding activity of single-chain (scFv) phage antibodies as measured by ELISA.				
Name phage antibody	<i>Enterococcus</i> strains (OD492 nm)		Control antigens (OD492 nm)	
	12030	T2	BSA	ELK
SC06-432	0.807	2.401	0.059	0.044
Average neg. ctrl	0.12	0.15	0.07	0.06

ND means not determined

TABLE 10

Data of the <i>Enterococcus</i> specific single-chain Fvs.				
Name scFv	SEQ ID NO of nucl. sequence	SEQ ID NO of amino acid sequence*	VH-locus	VL-locus
SC05-140	350	351 (Vh 1-121; Vl 138-243)	Vh3 (3-33)	Vl 3 (3h - V2-14)
SC05-157	352	353 (Vh 1-121; Vl 138-247)	Vh5 (5-51)	Vl 1 (1c - V1-16)
SC05-159	61	62 (Vh 1-123; Vl 140-249)	VH1 (1-f)	Vl 1 (1c - V1-16)
SC05-166	63	64 (Vh 1-133; Vl 150-259)	VH1 (1-18)	Vl 6 (6a - V1-22)
SC05-179	354	355 (Vh 1-117; Vl 134-244)	Vh3 (3-11)	Vl 2 (2e - V1-03)
SC05-187	65	66 (Vh 1-121; Vl 138-246)	VH5 (5-51)	Vl 7 (7a - V3-02)
SC06-016	67	68 (Vh 1-118; Vl 135-241)	VH1 (1-18)	Vk I (L5 - DPK5)
SC06-043	69	70 (Vh 1-123; Vl 140-249)	VH5 (5-51)	Vl 2 (2c - V1-02)
SC06-049	71	72 (Vh 1-120; Vl 137-246)	VH5 (5-51)	Vl 2 (2a2 - V1-04)
SC06-050	356	357 (Vh 1-126; Vl 143-249)	Vh1 (1-18)	Vk I (L8 - DPK8)
SC06-071	73	74 (Vh 1-122; Vl 139-248)	VH3 (3-33)	Vl 2 (2a2 - V1-04)
SC06-077	358	359 (Vh 1-119; Vl 136-248)	Vh1 (1-69)	Vk IV (B3 - DPK24)
SC06-078	75	76 (Vh 1-119; Vl 136-245)	VH1 (1-69)	Vl 2 (2a2 - V1-04)
SC06-079	360	361 (Vh 1-116; Vl 133-242)	Vh3 (3-23)	Vl 1 (1g - V1-17)

TABLE 10-continued

Data of the <i>Enterococcus</i> specific single-chain Fvs.				
Name scFv	SEQ ID NO of nucl. sequence	SEQ ID NO of amino acid sequence*	VH-locus	VL-locus
SC06-086	362	363 (Vh 1-120; Vl 137-243)	Vh1 (1-69)	Vk I (O12/O2 - DPK9)
SC06-087	206	207 (Vh 1-122; Vl 139-249)	Vh3 (3-21)	Vl 2 (2a2 - V1-04)
SC06-089	208	209 (Vh 1-123; Vl 140-247)	Vh3 (3-48)	Vl 3 (3h - V2-14)
SC06-092	364	365 (Vh 1-121; Vl 138-248)	Vh3 (3-49)	Vl 2 (2a2 - V1-04)
SC06-191	366	367 (Vh 1-120; Vl 137-243)	Vh3 (3-33)	Vk I (L12)
SC06-195	368	369 (Vh 1-115; Vl 132-241)	Vh3 (3-33)	Vl 1 (1g - V1-17)
SC06-198	370	371 (Vh 1-116; Vl 133-243)	Vh4 (4-b)	Vl 1 (1e - V1-13)
SC06-241	77	78 (Vh 1-118; Vl 135-241)	VH3 (3-30.3)	Vk I (L5 - DPK5)
SC06-242	372	373 (Vh 1-115; Vl 132-237)	Vh4 (4-59)	Vl 3 (3h - V2-14)
SC06-246	374	375 (Vh 1-121; Vl 138-245)	Vh3 (3-53)	Vl 3 (3h - V2-14)
SC06-252	79	80 (Vh 1-115; Vl 132-241)	VH3 (3-23)	Vl 1 (1c - V1-16)
SC06-388	376	377 (Vh 1-119; Vl 136-245)	Vh5 (5-51)	Vl 2 (2c - V1-02)
SC06-389	378	379 (Vh 1-121; Vl 138-245)	Vh5 (5-51)	Vl 3 (3l- V2-13)
SC06-396	380	381 (Vh 1-121; Vl 138-245)	Vh5 (5-51)	Vk III (A27 - DPK22)
SC06-402	382	383 (Vh 1-127; Vl 144-255)	Vh5 (5-51)	Vl 2 (2e - V1-03)
SC06-409	384	385 (Vh 1-122; Vl 139-249)	Vh5 (5-51)	Vl 2 (2a2 - V1-04)
SC06-415	386	387 (Vh 1-116; Vl 133-242)	Vh3 (3-09)	Vl 2 (2c - V1-02)
SC06-421	388	389 (Vh 1-120; Vl 137-246)	Vh5 (5-51)	Vl 2 (2c - V1-02)

TABLE 10-continued

Data of the <i>Enterococcus</i> specific single-chain Fvs.				
Name scFv	SEQ ID NO of nucl. sequence	SEQ ID NO of amino acid sequence*	VH-locus	VL-locus
SC06-429	390	391 (Vh 1-121; Vl 138-249)	Vh5 (5-51)	Vk II (A19/A03 - DPK15)
SC06-432	392	393 (Vh 1-120; Vl 137-246)	Vh4 (4-31)	Vl 1 (1e - V1-13)

*between brackets the amino acids making up the heavy chain variable region (VH) and the light chain variable region (VL) is shown

TABLE 11

Data of the CDR regions of the <i>Enterococcus</i> specific single-chain Fvs.						
Name scFv	HCDR1 (SEQ ID NO:)	HCDR2 (SEQ ID NO:)	HCDR3 (SEQ ID NO:)	LCDR1 (SEQ ID NO:)	LCDR2 (SEQ ID NO:)	LCDR3 (SEQ ID NO:)
SC05-140	218	219	220	221	222	223
SC05-157	224	225	226	227	228	229
SC05-159	1	2	3	4	5	6
SC05-166	7	8	9	10	11	12
SC05-179	230	231	232	233	234	235
SC05-187	13	14	15	16	17	18
SC06-016	19	20	21	22	23	24
SC06-043	25	26	27	28	29	30
SC06-049	31	32	33	34	35	36
SC06-050	236	237	238	239	240	241
SC06-071	37	38	39	40	41	42
SC06-077	242	243	244	245	246	247
SC06-078	43	44	45	46	47	48
SC06-079	248	249	250	251	252	253
SC06-086	254	255	256	257	258	259
SC06-087	194	195	196	197	198	199
SC06-089	200	201	202	203	204	205
SC06-092	260	261	262	263	264	265
SC06-191	266	267	268	269	270	271
SC06-195	272	273	274	275	276	277
SC06-198	278	279	280	281	282	283
SC06-241	49	50	51	52	53	54
SC06-242	284	285	286	287	288	289
SC06-246	290	291	292	293	294	295
SC06-252	55	56	57	58	59	60
SC06-388	296	297	298	299	300	301
SC06-389	302	303	304	305	306	307

TABLE 11-continued

Data of the CDR regions of the *Enterococcus* specific single-chain Fvs.

Name scFv	HCDR1 (SEQ ID NO:)	HCDR2 (SEQ ID NO:)	HCDR3 (SEQ ID NO:)	LCDR1 (SEQ ID NO:)	LCDR2 (SEQ ID NO:)	LCDR3 (SEQ ID NO:)
SC06-396	308	309	310	311	312	313
SC06-402	314	315	316	317	318	319
SC06-409	320	321	322	323	324	325
SC06-415	326	327	328	329	330	331
SC06-421	332	333	334	335	336	337
SC06-429	338	339	340	341	342	343
SC06-432	344	345	346	347	348	349

TABLE 12

Data of the *Enterococcus* specific IgGs.

Name IgG	SEQ ID NO of nucl. sequence heavy chain	SEQ ID NO of amino acid sequence* heavy chain	SEQ ID NO of nucl. sequence light chain	SEQ ID NO of amino acid sequence* light chain
CR5140	394	395 (Vh 1-121)	438	439 (Vl 1-106)
CR5157	396	397 (Vh 1-121)	440	441 (Vl 1-110)
CR5159	81	82 (Vh 1-123)	101	102 (Vl 1-110)
CR5166	83	84 (Vh 1-133)	103	104 (Vl 1-110)
CR5179	398	399 (Vh 1-117)	442	443 (Vl 1-111)
CR5187	85	86 (Vh 1-121)	105	106 (Vl 1-109)
CR6016	87	88 (Vh 1-118)	107	108 (Vl 1-107)
CR6043	89	90 (Vh 1-123)	109	110 (Vl 1-110)
CR6049	91	92 (Vh 1-120)	111	112 (Vl 1-110)
CR6050	400	401 (Vh 1-126)	444	445 (Vl 1-107)
CR6071	93	94 (Vh 1-122)	113	114 (Vl 1-110)
CR6077	402	403 (Vh 1-119)	446	447 (Vl 1-133)
CR6078	95	96 (Vh 1-119)	115	116 (Vl 1-110)
CR6079	404	405 (Vh 1-116)	448	449 (Vl 1-110)
CR6086	406	407 (Vh 1-120)	450	451 (Vl 1-107)
CR6087	210	211 (Vh 1-122)	214	215 (Vl 1-111)

TABLE 12-continued

Data of the <i>Enterococcus</i> specific IgGs.				
Name IgG	SEQ ID NO of nucl. sequence heavy chain	SEQ ID NO of amino acid sequence* heavy chain	SEQ ID NO of nucl. sequence light chain	SEQ ID NO of amino acid sequence* light chain
CR6089	212	213 (Vh 1-123)	216	217 (Vl 1-108)
CR6092	408	409 (Vh 1-121)	452	453 (Vl 1-111)
CR6191	410	411 (Vh 1-120)	454	455 (Vl 1-107)
CR6195	412	413 (Vh 1-115)	456	457 (Vl 1-110)
CR6198	414	415 (Vh 1-116)	458	459 (Vl 1-111)
CR6241	97	98 (Vh 1-118)	117	118 (Vl 1-107)
CR6242	416	417 (Vh 1-115)	460	461 (Vl 1-106)
CR6246	418	419 (Vh 1-121)	462	463 (Vl 1-108)
CR6252	99	100 (Vh 1-115)	119	120 (Vl 1-110)
CR6388	420	421 (Vh 1-119)	464	465 (Vl 1-110)
CR6389	422	423 (Vh 1-121)	466	467 (Vl 1-108)
CR6396	424	425 (Vh 1-121)	468	469 (Vl 1-108)
CR6402	426	427 (Vh 1-127)	470	471 (Vl 1-112)
CR6409	428	429 (Vh 1-122)	472	473 (Vl 1-111)
CR6415	430	431 (Vh 1-116)	474	475 (Vl 1-110)
CR6421	432	433 (Vh 1-120)	476	477 (Vl 1-110)
CR6429	434	435 (Vh 1-121)	478	479 (Vl 1-112)
CR6432	436	437 (Vh 1-120)	480	481 (Vl 1-110)

*between brackets the amino acids making up the heavy chain variable region (VH) and the light chain variable region (VL) is shown

TABLE 13

Specific binding activity against different strains of <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> by human IgG1 antibodies as measured by ELISA.						
Antibody Name	Enterococcal strains (OD492nm)					
	12030	T2	6814	B8610A	740220*	B210860*
CR5140	3.084	0.185	0.121	1.769	0.185	0.123
CR5157	0.225	0.358	0.215	0.282	0.199	0.086
CR5159	0.383	0.441	0.265	0.134	0.114	0.077
CR5166	0.533	1.387	0.444	0.140	0.170	0.101

55

TABLE 13-continued

Specific binding activity against different strains of <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> by human IgG1 antibodies as measured by ELISA.						
Antibody Name	Enterococcal strains (OD492nm)					
	12030	T2	6814	B8610A	740220*	B210860*
CR5179	0.250	1.206	0.285	1.546	0.131	0.091
CR5187	0.869	1.267	0.939	1.269	0.725	0.296
CR6016	0.281	0.622	0.243	0.134	0.126	0.084
CR6043	0.232	0.326	0.203	0.274	0.196	0.101

60

65

57

TABLE 13-continued

Specific binding activity against different strains of <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> by human IgG1 antibodies as measured by ELISA.						
Antibody Name	Enterococcal strains (OD492nm)					
	12030	T2	6814	B8610A	740220*	B210860*
CR6049	0.779	1.258	1.123	0.992	0.509	0.251
CR6050	0.291	0.739	0.218	0.117	0.138	0.092
CR6071	1.452	0.391	0.699	0.629	0.109	0.081
CR6077	0.739	1.774	0.436	0.137	0.137	0.086
CR6078	0.482	1.457	0.336	0.143	0.114	0.082
CR6079	0.751	0.597	0.293	1.160	0.186	0.114
CR6086	0.583	1.554	0.335	0.118	0.116	0.080
CR6087	1.085	1.414	0.098	0.135	0.182	0.091
CR6089	2.164	0.309	1.127	0.822	0.118	0.085
CR6092	2.779	1.204	1.989	1.599	0.113	0.088
CR6191	0.868	1.639	0.475	0.100	0.063	0.043
CR6195	0.304	1.652	0.084	2.219	0.051	0.042
CR6198	1.151	2.854	0.532	2.849	0.071	0.039
CR6241	0.814	0.091	0.043	0.072	0.060	0.037
CR6242	0.356	0.102	0.047	0.075	0.079	0.038
CR6246	0.207	0.290	0.047	0.083	0.131	0.049
CR6252	0.583	0.370	0.045	0.076	0.690	0.052
CR6388	0.165	0.180	0.139	0.157	0.207	0.116
CR6389	0.562	0.197	0.122	0.182	0.168	0.320
CR6396	0.427	0.640	0.342	0.500	0.456	0.312
CR6402	0.428	0.391	0.236	0.447	0.292	0.270
CR6409	0.120	0.155	0.113	0.145	0.169	0.124
CR6415	2.284	1.910	0.122	0.108	1.119	0.195
CR6421	0.693	0.803	0.511	0.822	0.438	0.368
CR6429	0.302	0.437	0.190	0.403	0.347	0.185
CR6432	0.358	0.364	0.322	0.500	0.216	0.406
Average neg. ctrl	0.11	0.13	0.09	0.13	0.12	0.07

58

TABLE 14

In vitro opsonophagocytic killing activity against <i>Enterococcus faecalis</i> strain 12030 by human IgG1 antibodies.	
Antibody Name	Antibody Concentrations (ng/ml) giving 50% bacterial killing
CR5140	ND
CR5157	20.7
CR5159	130
CR5166	27.8
CR5179	312
CR5187	295
CR6016	2.20
CR6043	8.94
CR6049	3794
CR6050	5.82
CR6071	12.4
CR6077	54.7
CR6078	10.5
CR6079	>10000
CR6086	10.8
CR6087	21.2
CR6089	3.67
CR6092	>10000
CR6191	178
CR6195	>10000
CR6198	4787
CR6241	0.613
CR6242	ND
CR6246	>10000
CR6252	29.2
CR6388	0.64
CR6389	0.33
CR6396	4.71
CR6402	1.00
CR6409	36.6
CR6415	ND
CR6421	21.6
CR6429	1.2
CR6432	>10000

ND means not determined

TABLE 15

Killing activity of IgG1 antibodies as measured by opsonophagocytic killing assay.								
Strain	Mean enterococcal and staphylococcal killing activity (%)							
	Type 2		740220		838970		502	
[ng/ml]	2500	25	2500	25	2500	25	2500	25
CR5140	14.9	7.7	72.2	44.1	11.9	2.3	66.4	44.9
CR5157	2.3	4.0	64.8	14.5	27.7	9.7	48.7	27.0
CR6016	15.7	4.6	66.9	17.9	3.2	1.7	59.0	32.3
CR6043	30.0	16.1	63.6	15.7	21.1	2.8	50.5	21.3
CR6050	7.5	5.8	49.4	18.8	33.1	8.1	59.0	28.2
CR6078	43.2	24.9	60.4	25.6	4.6	1.5	39.2	12.8
CR6087	54.4	41.1	58.8	30.3	34.7	16.0	26.5	12.3
CR6089	7.3	6.3	60.4	19.4	32.2	7.4	32.8	8.2
CR6241	6.5	4.3	73.5	44.8	48.5	18.3	38.2	9.6
CR6252	9.8	6.9	74.6	43.6	43.1	25.5	46.5	19.7
CR6388	50.8	22.6	54.8	18.0	47.2	7.3	51.8	34.1
CR6389	10.5	7.7	56.8	30.8	37.7	19.3	35.4	16.7
CR6396	6.8	2.9	36.6	9.4	30.9	5.2	37.6	13.1
CR6402	39.0	24.9	57.9	21.0	36.4	12.9	20.8	6.0
CR6409	46.0	27.6	64.5	36.9	25.0	3.7	46.9	18.4
CR6415	16.9	12.2	56.6	24.2	35.3	19.6	42.4	20.4
CR6421	5.3	2.9	64.3	14.0	35.7	21.0	44.9	21.5
CR6429	-0.1	-1.2	58.7	5.7	43.5	12.3	36.5	12.6

REFERENCES

Boel E, Verlaan S, Poppelier M J, Westerdal N A, Van Strijp J A and Logtenberg T (2000), Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. *J. Immunol. Methods* 239:153-166.

Burton D R and Barbas C F (1994), Human antibodies from combinatorial libraries. *Adv. Immunol.* 57:191-280.

Chou, T C and P Talalay (1984), Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv. Enzyme Regul.* 22:27-55.

De Kruif J, Terstappen L, Boel E and Logtenberg T (1995a), Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. *Proc. Natl. Acad. Sci. USA* 92:3938.

De Kruif J, Boel E and Logtenberg T (1995b), Selection and application of human single-chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. *J. Mol. Biol.* 248:97-105.

Huebner J, Wang Y, Krueger W A, Madoff L C, Martirosian G, Boisot S, Goldmann D A, Kasper D L, Tzianabos A O and Pier G B (1999), Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of *Enterococcus faecalis* and vancomycin-resistant *Enterococcus faecium*. *Infect. Immun.* 67:1213-1219.

Hufnagel M, Koch S, Creti R, Baldassarri L, and Huebner J (2004), A putative sugar-binding transcriptional regulator in a novel gene locus in *Enterococcus faecalis* contributes to production of biofilm and prolonged bacteremia in mice. *J. Infect. Dis.* 189:420-430.

Huls G, Heijnen I J, Cuomo E, van der Linden J, Boel E, van de Winkel J and Logtenberg T (1999), Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. *Cancer Res.* 59:5778-5784.

Slootstra J W, Puijk W C, Ligtoet G J, Langeveld J P, Meloen R H (1996), Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. *Mol. Divers.* 1:87-96.

a heavy chain CDR1 region comprising SEQ ID NO: 55;
a heavy chain CDR2 region comprising SEQ ID NO: 56;
a heavy chain CDR3 region comprising SEQ ID NO: 57;
a light chain CDR1 region comprising SEQ ID NO: 58;
a light chain CDR2 region comprising SEQ ID NO: 59; and
a light chain CDR3 region comprising SEQ ID NO: 60.

2. The human monoclonal antibody of claim 1, comprising:

a heavy chain comprising a variable heavy chain of SEQ ID NO: 100, and

a light chain comprising a variable light chain of SEQ ID NO: 120.

3. The human monoclonal antibody of claim 1, wherein the *Enterococcus* species comprise *E. faecalis* and *E. faecium*.

4. The human monoclonal antibody of claim 2, wherein the *Enterococcus* species comprise *E. faecalis* and *E. faecium*.

5. A pharmaceutical composition comprising:

the human monoclonal antibody of claim 1, wherein the human monoclonal antibody has opsonic phagocytic killing activity against *Enterococcus* species and against at least one strain of *S. aureus*, and

at least one pharmaceutically acceptable excipient.

6. The pharmaceutical composition of claim 5, further comprising:

at least one other therapeutic agent.

7. An immunoconjugate comprising:

the human monoclonal antibody of claim 1, and at least one tag.

8. An immunoconjugate comprising:

the human monoclonal antibody of claim 2, and at least one tag.

9. An immunoconjugate comprising:

the human monoclonal antibody of claim 3, and at least one tag.

SEQUENCE LISTING

The patent contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US08628776B2>). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed is:

1. A human monoclonal antibody against *Enterococcus* species and against at least one strain of *Staphylococcus aureus*, wherein the antibody comprises:

10. An immunoconjugate comprising:
the human monoclonal antibody of claim 4, and at least one tag.

* * * * *